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I. The Need for Medication Treatment  
of Opioid Addiction 
Opioid overdoses have quadrupled over the last decade in the 
U.S.1  The Drug Enforcement Agency has reported that more people 
died from drug overdoses in the U.S. in 2013—mostly caused by 
opioids—than from car accidents.2  Some states have been hit 
especially hard, such as Kentucky, where deaths from heroin 
overdoses increased by 550% from 2011 to 2012.3  Most individuals 
who overdose on opioids in the U.S. are addicted to either heroin or 
prescription painkillers, such as oxycodone.4   
Approximately 2.1 million individuals in the U.S. are dependent 
on opioid prescription pain killers, and 467,000 are dependent on 
heroin.5 Opioid dependence has many negative (and often tragic) 
 
1. Li Hui Chen et al., Nat’l Cent. for Health Stat., Drug-Poisoning Deaths 
Involving Opioid Analgesics: United States 1999-2011 NCHS DATA 
BRIEF 1 (2014), http://www.cdc.gov/nchs/data/databriefs/db166.pdf. 
2. DRUG ENFORCEMENT AGENCY, 2015 NATIONAL DRUG THREAT 
ASSESSMENT iii (2015), http://www.dea.gov/docs/2015%20NDTA 
%20Report.pdf. See also Understanding the Epidemic: Overdose deaths 
in the United States hit record numbers in 2014, CDC.GOV, 
http://www.cdc.gov/drugoverdose/epidemic/index.html (“The majority 
of drug overdose deaths (more than six out of ten) involve and opioid… 
78 Americans die every day from an opioid overdose”). 
3. DRUG FREE KENTUCKY, NORTHERN KENTUCKY’S COLLECTIVE RESPONSE 
TO THE HEROIN EPIDEMIC 14 (2013), http://drugfreenky.org/wp-
content/uploads/2013/11/Northern-Kentuckys-Collective-Response-
Final.pdf. 
4. See Chen et al., supra note 1. 
5. America’s Addiction to Opioids: Heroin and Prescription Drug Abuse: 
Hearing on Heroin and Prescription Drug Abuse Before the Senate 
Caucus on International Narcotics Control (2014) (statement of Nora 
Volkow, Director, National Institute on Drug Abuse)  
[hereinafter Hearing on Heroin and Prescription Drug Abuse, 
http://www.drugabuse.gov/about-nida/legislative-activities/testimony-
to-congress/2014/americas-addiction-to-opioids-heroin-prescription-drug-
abuse. 
Health Matrix·Volume 26·Issue 1·2016 
America Needs the TREAT Act:  
Expanding Access to Effective Medication for Treating Addiction 
311 
consequences for the opioid-dependent individual, his or her family, 
and society.6  Costs to the dependent individual include productivity 
loss, increased medical costs (especially from emergency room visits 
and hospitalization), mental distress, and sometimes death.7  Costs to 
society include decreased economic productivity, increased medical 
costs, and drug-related crimes.8  Some cities, like Connersville, 
Indiana, have been economically devastated by the ripple effects of 
opioid addiction.9   
Treatment exists for opioid dependence, but it is underutilized.10  
In 2013, an estimated 22.7 million Americans were dependent on or 
abused illicit drugs or alcohol, but only 3 million Americans received 
treatment for drug dependence.11  However, not all treatments for 
drug dependence are equally effective, and many common 
misconceptions about effective treatment exist.12   
 
6. See, e.g., SUBSTANCE ABUSE AND MENTAL HEALTH SERVS. ADMIN., 
SUBSTANCE ABUSE PREVENTION DOLLARS AND CENTS: A COST-BENEFITS 
ANALYSIS 6-9 (2008), http://www.samhsa.gov/sites/default/files/cost-
benefits-prevention.pdf.; HG Birnbaum et al., Societal Costs of 
Prescription Opioid Abuse, Dependence, and Misuse in the United 
States, 12 PAIN MED. 657, 658 (2011). 
7. See Birnbaum et al., supra note 6. 
8. See id. at 660-61; Jack Rinehart, Connersville ODs Rise to 36 in Just 
2Months, THE INDY CHANNEL (Nov. 6, 2014), 
http://www.theindychannel.com/news/local-news/connersville-heroin-
ods-rise-to-36-in-two-months. (“85 percent of the city’s crime rate is tied 
directly to heroin use.”) 
9. See Network Indiana, Sen. Donnelly Addresses Heroin Overdoses in 
Connersville, INDIANA PUB. MEDIA (Nov. 7, 2014), 
http://indianapublicmedia.org/news/heroin-problems-continue-
connersville-74402/. 
10. See Hearing on Heroin and Prescription Drug Abuse, supra note 5.  
11. See Behavioral Health Treatments and Services, SUBSTANCE ABUSE AND 
MENTAL HEALTH SERVS. ADMIN. (Oct. 16, 2014) 
http://www.samhsa.gov/treatment. 
12. See Maia Szalavitz, After 75 Years of Alcoholics Anonymous, It’s Time 
to Admit We Have a Problem: Challenging the 12-Step Hegemony, 
PACIFIC STANDARD (Feb. 10, 2014), http://www.psmag.com/books-and-
culture/75-years-alcoholics-anonymous-time-admit-problem-74268; 
Harlan Matusow et al., Medication Assisted Treatment in US Drug 
Courts: Results from a Nationwide Survey of Availability, Barriers and 
Attitudes, 44 J. SUBSTANCE ABUSE TREATMENT 473, 479 (2013) 
(“Despite evidence of the safety and efficacy of methadone and 
buprenorphine to improve outcomes for opioid dependence, we found 
that MAT has limited penetration in drug courts. Lack of adoption of 
an effective treatment intervention is troubling in light of the increasing 
problem of opioid abuse in the United States, the large body of growing 
evidence demonstrating MAT’s efficacy in treating it, and the high 
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One common misconception is that twelve-step treatment models, 
such as Narcotics Anonymous (NA) and its identical twin Alcoholics 
Anonymous (AA), are scientifically proven treatments for opioid 
dependence.13  In fact, many scientists do not consider NA and AA to 
be evidenced-based treatment for opioid dependence.14 The National 
Institute on Drug Abuse describes twelve-step groups as merely a 
supplement to effective addiction treatment.15  However, twelve-step 
groups are the primary form of treatment for drug dependence in 90% 
of in-patient rehabilitation centers in the U.S.16  Very little proof 
exists that twelve-step groups prevent drug abuse, and many 
purported studies of effectiveness have failed to distinguish between 
causation and correlation.17   The Journal of Addiction published the 
results of four rigorous, experimental studies of AA for the treatment 
of alcoholism; only two studies found a significant positive effect of 
AA on abstinence, one found a negative effect, and one found no 
 
relapse rates that occur when patients are withdrawn from agonist 
therapy even when counseling (without MAT) is still available.”). 
13. See Szalavitz, supra note 12, at 68. 
14. See NAT’L INST. ON DRUG ABUSE, U.S. DEP’T OF HEALTH & HUMAN 
SERVS., PRINCIPLES OF DRUG ADDICTION TREATMENT: A RESEARCH-
BASED GUIDE, EVIDENCE-BASED APPROACHES TO DRUG ADDICTION 
TREATMENT 27, 58 (3d ed. 2012) [hereinafter PRINCIPLES OF DRUG 
ADDICTION TREATMENT], 
http://www.drugabuse.gov/publications/principles-drug-addiction-
treatment-research-based-guide-third-edition/evidence-based-approaches-
to-drug-addiction-treatment.  (“While the efficacy of 12-step programs 
(and 12-step facilitation) in treating alcohol dependence has been 
established, the research on its usefulness for other forms of substance 
abuse is more preliminary, but the treatment appears promising for 
helping drug abusers sustain recovery.”). 
15. See id. at 27. 
16. See Jason Cherkis, Dying to Be Free, HUFFINGTON POST (Jan. 28, 
2015), https://projects.huffingtopost.com/dying-to-be-free-heroin-
treatment (“Peer-reviewed data and evidence-based practices do not 
govern how rehabilitation facilities work.”).  
17. Lee Ann Kaskutas, Alcoholics Anonymous Effectiveness: Faith Meets 
Science, 28 J. ADDICTION 145, 152 (2008) (“What, then, is the scorecard 
for AA effectiveness in terms of specificity? Among the rigorous 
experimental studies, there were two positive findings for AA 
effectiveness, one null finding, and one negative finding. Among those 
that statistically addressed selection bias, there were two contradictory 
findings, and two studies that reported significant effects for AA after 
adjusting for potential confounders such as motivation to change. 
Readers must judge for themselves whether their interpretation of these 
results, on balance, supports a recommendation that there is no 
experimental evidence of AA effectiveness (as put forward by the 
Cochrane review).”). 
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effect.18  The National Institute on Drug Abuse has stated that even 
fewer studies of NA (the group for drug dependent individuals) exist 
than of AA (the group for alcohol dependent individuals).19 
Another common misconception about drug dependence is that 
detoxification in a controlled setting is sufficient treatment to prevent 
relapse.20  However, detoxification alone is almost never enough to end 
drug dependence, especially opioid dependence, because the physical 
changes in the brain persist post-detoxification.21  Additionally, the 
chance of overdose is highest immediately after detoxification, because 
psychological and physical cravings exist but physical tolerance for 
opioids is low.22   
Instead of NA/AA or detoxification alone, the medical standard 
of care for opioid addiction is medication combined with counseling, 
frequently referred to as medication assisted treatment (MAT).23  This 
 
18. See id. 
19. See also PRINCIPLES OF DRUG ADDICTION TREATMENT, supra note 14, at 
57-58. 
20. See LOUISE BAXTER & ALAN STEVENS, AM. SOC’Y OF ADDICTION MED., 
THE IMPACT OF MANAGED CARE ON ADDICTION TREATMENT: AN 
ANALYSIS 2 (2012),  http://www.asam.org/docs/advocacy/2012-9-
25_nj-opiate-document.pdf?sfvrsn=2; Vt. Agency of Human Services, 
Integrated Treatment Continuum for Substance Use Dependence 
“Hub/Spoke” Initiative—Phase 1: Opiate Dependence (Jan. 2012), at 2, 
http://www.healthvermont.gov/adap/documents/HUBSPOKEBriefingD
ocV122112.pdf (“Medication assisted therapy (MAT), such as 
methadone and buprenorphine in combination with counseling, has long 
been recognized as the most effective treatment for opiate addiction.”); 
What are the treatments for heroin addiction?, NAT’L INST. ON DRUG 
ABUSE (last updated Nov. 2014), http://www.drugabuse.gov/ 
publications/research-reports/heroin/what-are-treatments-heroin-
addiction. 
21. See Dan Lubman et al., Addiction, a condition of compulsive behaviour? 
Neuroimaging and neuropsychological evidence of inhibitory 
dysregulation, 99 ADDICTION 1491, 1492 (2004). 
22. BAXTER & STEVENS, supra note 20, at 2 (“Unfortunately, too many 
stakeholders in addiction treatment represent that detoxification alone is 
treatment. “Detoxification alone” only increases the probability of 
relapse into active use and overdose deaths.”); Matusow et al., supra 
note 12, at 478 (“In light of the ample evidence demonstrating high 
relapse rates following opioid detoxification, a policy mandating medical 
withdrawal [from M.A.T.] appears to be contrary to be practices as 
defined by medical evidence and the consensus of addiction experts and 
may represent an infringement of rights as set forth in the Americans 
with Disabilities Act.”). 
23. See BAXTER & STEVENS, supra note 20, at 4; Lisa A. Marsch, The 
Efficacy of Methadone Maintenance Interventions in Reducing Illicit 
Opiate Use, HIV Risk Behavior, and Criminality, 93 ADDICTION 515 
(1998); Richard P. Mattick et al., Methadone Maintenance Therapy 
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standard has been acknowledged by the American Society of 
Addiction Medicine and the American Medical Association for over a 
decade but has been largely ignored by most in-patient treatment 
centers.24  In March 2015, the U.S. Department of Health and Human 
Services affirmed that “MAT is the most effective form of treatment 
for opioid use disorders.”25 The most effective medications used as 
part of MAT for treating opioid addiction are buprenorphine 
(commonly known by the brand name Suboxone), Vivitrol (extended-
release naltrexone), and methadone.26  Each of these three medicines 
has been proven significantly more effective at preventing relapse than 
a placebo in rigorous, double-blind experimental studies.27   Medical 
 
versus No Opioid Replacement Therapy for Opioid Dependence, 
COCHRANE DATABASE OF SYSTEMATIC REVIEWS 1, 5, 10-11 (2009) 
(noting that medication maintained treatment combined with therapy is 
more effective than therapy alone); Richard P. Mattick et al., 
Burprenorphine Maintenance versus Placebo or Methadone Maintenance 
for Opioid Addiction, COCHRANE DATABASE OF SYSTEMATIC REVIEWS 1, 
1, 17, 19 (2009) (noting effectiveness of buprenorphrone vs. placebo); 
National Consensus Development Panel on Effective Medical Treatment 
of Opiate Addiction, Effective Medical Treatment for Opiate Addiction, 
280 JAMA 1936 (1998); Jeffrey Baxter et al., Factors Associated with 
Medicaid Patients’ Access to Buprenorphine Treatment, 41 J. 
SUBSTANCE ABUSE TREATMENT 88 (2011); Heino Stöver, Barriers to 
Opioid Substitution Treatment Access, Entry and Retention: A Survey 
of Opioid Users, Patients in Treatment, and Treating and Non-Treating 
Physicians, 17 EUR. ADDICTION RES. 44, 44 (2011) (“Opioid substitution 
treatment (OST) is recognized internationally as the most effective and 
cost-effective intervention to reduce the social, health and economic 
burden associated with opioid dependence.”); Saxon & McCarty, supra 
note 16, at 122. 
24. See generally BAXTER & STEVENS, supra note 20; What are the 
treatments for heroin addiction?, supra note 20. 
25. U.S. DEP’T OF HEALTH & HUMAN SERVS., EXECUTIVE SUMMARY: OPIOID 
ABUSE IN THE U.S. AND HHS ACTIONS TO ADDRESS OPIOID-DRUG 
RELATED OVERDOSES AND DEATHS 3 (2015), http://aspe.hhs.gov/sp/ 
reports/2015/OpioidInitiative/es_OpioidInitiative.pdf. 
26. See What are the treatments for heroin addiction?, supra note 20. 
27. See generally CENT. FOR SUBSTANCE ABUSE TREATMENT, MEDICATION-
ASSISTED TREATMENT FOR OPIOID ADDICTION IN OPIOID TREATMENT 
PROGRAMS 32-33 (2012) [hereinafter MEDICATION ASSISTED TREATMENT 
FOR OPIOID ADDICTION], http://www.ncbi.nlm.nih.gov/books/ 
NBK64164/pdf/TOC.pdf; Angela Stotts et al., Opioid Dependence 
Treatment: Options in Pharmacotherapy, 10 EXPERT OPINION 
PHARMACOTHER. 1727 (2009); Kimberly L. Kjome & F. Gerard Moeller, 
Long-Acting Injectable Naltrexone for the Management of Patients with 
Opioid Dependence, 5 SUBSTANCE ABUSE: RES. & TREATMENT 1, 4 
(2011); Richard Boldt, The “Tomahawk” and the “Healing Balm”: Drug 
Treatment Courts in Theory and Practice, 10 U. MD. L.J. RACE, 
RELIGION, GENDER & CLASS 45, 60 (2010) (“Indeed, methadone 
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studies have also found that the combination of medication and 
counseling is more effective than counseling alone at preventing 
relapse.28  The retention rate for treatment with medication is greater 
than the retention rate for medication-free treatment.29 Unfortunately, 
all medications for treating opioid dependence are underutilized by 
dependent individuals, under-prescribed by physicians, rarely 
available within in-patient rehabilitation centers,30 and rarely used 
within prisons or drug courts.31  According to the Huffington Post, in 
 
maintenance treatment consistently has been demonstrated to reduce 
drug use and criminal activity among opiate addicts far more effectively 
than other forms of drug-free outpatient therapy.”); Lauren Amato et 
al., An Overview of Systematic Reviews of the Effectiveness of Opiate 
Maintenance Therapies: Available Evidence to Inform Clinical Practice 
and Research, 28 J. SUBSTANCE ABUSE TREATMENT 321, 323 (2005); 
Stephen Magura et al., The Effectiveness of In-Jail Methadone 
Maintenance, 23 J. DRUG ISSUES 75 (1993) (prisoners in a methadone 
maintenance program were more likely to participate in post-release 
treatment program, which was associated with lower drug use). 
28. See PRINCIPLES OF DRUG ADDICTION, supra note 14, at 10 (“Because 
they work on different aspects of addiction, combinations of behavioral 
therapies and medications (when available) generally appear to be more 
effective than either approach used alone.”); Morten Hesse & Mads Uffe 
Pederson, Easy-access Services in Low-threshold Opiate Agonist 
Maintenance, 6 INT’L J. MENTAL HEALTH ADDICTION 316 (2008) (study 
of combining methadone treatment with counseling in Europe). 
29. Sebastian Trautmann & Hans-Ulrich Wittchen, An Analysis of German 
Settings Providing Opioid Maintenance Therapy, 47 SUBSTANCE USE & 
MISUSE 22, 23 (2012); John R. Caplehorn, A Comparison of Abstinence-
Oriented and Indefinite Methadone Maintenance Treatment, 29 INT’L J. 
ADDICTIONS 1361 (1994); John R. Caplehorn et al., Clinic Policy and 
Retention in Methadone Maintenance, 28 INT’L J. ADDICTIONS 73 
(1993); Mark L. Willenbring et al., Variations in Evidence-Based 
Clinical Practices in Nine United States Veterans Administration 
Opioid Agonist Therapy Clinics, 75 DRUG & ALCOHOL DEPENDENCE 97, 
99 (2004). 
30. See Cherkis, supra note 16 (“Peer-reviewed data and evidence-based 
practices do not govern how rehabilitation facilities work.”). 
31. See Amy Nunn et al., Methadone and Buprenorphine Prescribing and 
Referral Practices in US Prison Systems: Results from a Nationwide 
Survey, 105 DRUG & ALCOHOL DEPENDENCE 83, 85; National Association 
of Drug Court Professionals, Resolution of the Board of Directors on the 
Availability of Medically Assisted Treatment (M.A.T.) for Addiction in 
Drug Courts (July 17, 2011), http://www.nadcp.org/sites/default/files/ 
nadcp/NADCP%20Board%20Statement%20on%20MAT.pdf; Substance 
Abuse & Mental Health Servs. Admin., Adult Drug Courts and 
Medication-Assisted Treatment for Opioid Dependence, 8 IN BRIEF 4-5 
(2014) [hereinafter Adult Drug Courts and Medication-Assisted 
Treatment for Opioid Dependence]; Drug Courts Help Break Down 
Barriers to MAT in Criminal Justice System, 22 ALCOHOLISM & DRUG 
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2012 the National Center on Addiction and Substance Abuse at 
Columbia University published a report that the U.S. treatment 
system needed “significant overhaul” and suggested that the “low 
levels of care that addiction patients usually do receive constitutes a 
form of medical malpractice.”32  
This article focuses on the underuse of one medication in 
particular, buprenorphine, because it is the most widely used 
medication for treating opioid dependence33 that is cost-effective.34  
Buprenorphine treatment decreases relapse,35 cravings,36 mortality,37 
drug-related crimes,38 and Medicaid costs.39  It is a life-saving, 
 
ABUSE WEEKLY 1, 6 (Nov. 1, 2010); Matusow et al., supra note 12, at 
475-76 (approximately half of drug courts forbid the use of M.A.T.). 
32. See Cherkis, supra note 16.  See also Saxon & McCarty, supra note 16, 
at 123. 
33. See Cherkis, supra note 16. 
34. For comparison of buprenorphine to methadone, cf. Paul G. Barnett, 
Comparison of Costs and Utilization Among Buprenorphine and 
Methadone Patients, 104 ADDICTION 982, 989-92 (2009).  For cost of 
Vivitrol, see Join Together Staff, Study Finds Extended Release 
Naltrexone Can Save Overall Healthcare Costs, PARTNERSHIP FOR DRUG-
FREE KIDS (May 15, 2014), http://www.drugfree.org/join-
together/study-finds-extended-release-naltrexone-can-save-overall-
healthcare-costs/; Paul G. Barnett et al., The cost-effectiveness of 
buprenorphine maintenance therapy for opiate addiction in the United 
States, 96 ADDICTION 1267 (2001). 
35. See Paul Fudala et al., Office-Based Treatment of Opiate Addiction 
with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone, 
349 NEW ENG. J. MED. 949 (2003). 
36. See id. 
37. See Amy Gibson et al., Exposure to Opioid Maintenance Treatment 
Reduces Long-Term Mortality, 103 ADDICTION 462, 465 (2008). 
38. See, e.g., Michael S. Gordon et al., Buprenorphine Treatment for 
Probationers and Parolees, 36 SUBSTANCE ABUSE 217 (2015). Cf.  Erol 
Digiusto et al., Effects of Pharmacotherapies for Opioid Dependence on 
Participants’ Criminal Behavior and Expenditure on Illicit Drugs: An 
Australian National Evaluation (NEOPD), 39 AUSTL. & N.Z. J. 
CRIMINOLOGY 171 (2006) (discussing impact of methadone in lowering 
criminal activity). 
39. Informational Bulletin, Center for Medicaid & CHIP Services, 
Medication Assisted Treatment for Substance Use Disorders, 1 (July 11, 
2014), http://medicaid.gov/Federal-Policy-Guidance/Downloads/CIB-
07-11-2014.pdf (citing Walter, L. et al., Medicaid Chemical Dependency 
Patients in a Commercial Health Plan, 32 J. BEHAV. HEALTH SERVS. & 
RES. 253 (2005)). 
Health Matrix·Volume 26·Issue 1·2016 
America Needs the TREAT Act:  
Expanding Access to Effective Medication for Treating Addiction 
317 
essential medicine according to the World Health Organization.40  The 
United Nations has recommended that all nations make 
buprenorphine treatment widely accessible, especially within prisons.41   
Surprisingly, utilization of buprenorphine is very low in the U.S.,42 
partly due to restrictions placed on prescribers under the Drug 
Addiction Treatment Act (DATA) of 2000.43 In 2013, Senator Markey 
introduced the Recovery Enhancement for Addiction Treatment Act 
(TREAT Act) in the Senate, which would loosen DATA’s patient 
limit restrictions and expand prescribing ability to nurse practitioners 
and physician assistants.44  Even though the bill was strongly 
supported by the American Medical Association, American Society of 
Addiction Medicine, and other professional organizations45, it received 
scant media or public attention.46  The TREAT Act was reintroduced 
 
40. See WHO Model List of Essential Medicines, WORLD HEALTH ORG. 
(2013), http://apps.who.int/iris/bitstream/10665/93142/1/ 
EML_18_eng.pdf?ua=1.   
41. See WORLD HEALTH ORG., U.N. OFF. ON DRUGS AND CRIME & U.N. 
AIDS, POSITION PAPER: SUBSTITUTION MAINTENANCE THERAPY IN THE 
MANAGEMENT OF OPIOID DEPENDENCE AND HIV/AIDS PREVENTION 2 
(2004) [hereinafter WHO/UNODC/UNAIDS POSITION PAPER: 
SUBSTITUTION MAINTENANCE THERAPY], http://www.unodc.org/ 
documents/hiv-ids/Position%20Paper%20sub.%20maint.%20therapy.pdf. 
See also ANDREJ KASTELIC ET AL., OPIOID SUBSTITUTION TREATMENT IN 
CUSTODIAL SETTINGS: A PRACTICAL GUIDE 68 (2008), 
http://www.unodc.org/documents/hiv-aids/ 
OST_in_Custodial_Settings.pdf. 
42. See Ad Fox et al., I Heard About it from a Friend: Assessing Interest in 
Buprenorphine Treatment, 35 SUBSTANCE ABUSE 74, 74 (2014). 
43. See, e.g., Letter from Stuart Gitlow, President, American Society of 
Addiction Medicine, to Senator Edward J. Markey, (June 19, 2014) 
[hereinafter ASAM Letter], http://www.asam.org/docs/default-
source/advocacy/letters-and-comments/buprenorphine-expansion-act-
markey-letter.pdf (“We have at our disposal highly effective, FDA-
approved pharmacotherapies to treat opioid addiction. Unfortunately, 
they all come with arbitrary treatment limits that have resoundingly 
negative effects on treatment access and outcomes.”).   
44. See Recovery Enhancement for Addiction Treatment Act, S.2645, 113th 
Cong. (2014). 
45. See Press Release, Sen. Ed Markey, Markey Introduces Legislation to 
Expand Treatment for Heroin and Prescription Drug Addiction (July 
23, 2014), http://www.markey.senate.gov/news/press-releases/markey-
introduces-legislation-to-expand-treatment-for-heroin-and-prescription-
drug-addiction. 
46. A Google search by the author on February 9, 2015, did not result in 
any mainstream newspaper headlines regarding the TREAT Act. 
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in 2015 in the Senate (where it is currently in committee47), and a 
companion legislation was introduced in 2015 in the House of 
Representatives (where it is also currently in committee).48 Medical 
professional organizations are once again strongly supporting the 
TREAT Act.49   
The article begins in Part II with an overview of the three most 
effective medicines approved by the Food and Drug Administration 
(FDA) for treating opioid dependence.  The section then compares 
costs and benefits of buprenorphine relative to methadone and 
Vivitrol.  Part III describes existing legal restrictions placed on 
buprenorphine prescriptions by the Drug Enforcement Agency and by 
Congress through the Drug Addiction and Treatment Act of 2000.  
Part IV discusses general reasons for buprenorphine’s underutilization, 
including legal restrictions, cultural stigma, and cost.50  Finally, Part 
V analyzes the proposed TREAT Act and suggests ways to further 
improve it. 
II. Overview of Effective Medications 
The three most effective FDA-approved medications for treating 
opioid dependence are methadone, Vivitrol, and buprenorphine.51  
These medications are discussed and compared below. 
 
47. See Major Actions - 
Recovery Enhancement for Addiction Treatment Act, S.1445, 
CONGRESS.GOV (2015), https://www.congress.gov/bill/114th-congress/ 
senate-bill/1455/all-actions?q={%22search%22%3A[%22RECOVERY+ 
ENHANCEMENT+FOR+ADDICTION+TREATMENT+ACT+S2645
%22]}&resultIndex=2 (last visited October 20, 2015) (“Read twice and 
referred to the Committee on Health, Education, Labor, and 
Pensions.”). 
48. See Major Actions 
Recovery Enhancement for Addiction Treatment Act, H.R. 2536, 
CONGRESS.GOV (2015), available at https://www. 
congress.gov/bill/114th-congress/house-bill/2536/all-actions?q= 
{%22search%22%3A[%22\%22hr2536\%22%22]}&resultIndex=1.  
49. Johanna Zussman-Dobbins, Action Requested: Support the TREAT Act, 
AM. SOC’Y ADDICTION MED. MAG. (June 10, 2015), 
http://www.asam.org/magazine/read/article/2015/06/10/action-
requested-support-the-treat-act. 
50. Matusow et al., supra note 12, at 473-74 (“Despite the demonstrated 
benefits of agonist therapy (and virtual absence of evidence for the 
efficacy of stand-alone behavioral interventions), concerns persist.  
Among these concerns are diversion, risk of overdose, the extended 
duration of treatment, and limited progress patients may make in 
achieving other treatment goals such as cessation from non-opioid 
substance abuse and obtaining gainful employment.”).  
51. See What are the treatments for heroin addiction?, supra note 20.  
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A. Methadone  
Methadone is the oldest FDA-approved medication for treating 
opioid dependence.52  It works by activating the opioid receptor in the 
brain, called the mu-receptor.53  Methadone is a complete mu-agonist, 
meaning that it completely activates the mu-receptor.54   As a result, 
it prevents cravings for opioids, while allowing an individual to stop 
using heroin and painkillers without experiencing withdrawal 
symptoms.55  Because methadone has a higher selectivity for the mu-
receptor than do heroin or painkillers, methadone prevents euphoria 
or a “high” if a person abuses heroin or painkillers while on 
methadone treatment.56  A person undergoing methadone treatment 
can function normally and does not feel or appear “high.”57  
Methadone treatment has been proven to decrease death rates, 
relapse, drug-related crimes, HIV/AIDS from shared needles, medical 
costs, and unemployment.58  According to the National Institute on 
Drug Abuse, every dollar invested in methadone treatment saves 
society 38 dollars.59 
Methadone can be dangerous if diverted and improperly used; but 
most individuals who obtain methadone use it for treatment and do 
not abuse it.60  Because methadone has a high potential for physical 
and psychological dependence, it is a Schedule II narcotic under the 
Controlled Substances Act (CSA), where Schedule I is the most 
legally restrictive and Schedule V is the least restrictive.61  In order to 
prevent illicit diversion, methadone is only available at certified 
methadone treatment centers, to which the patient must usually 
return daily in order to continue treatment.62  These treatment 
 
52. See generally Joseph Herman et al., Methadone Maintenance Treatment 
(MMT): A Review of Historical and Clinical Issues.  67 MOUNT SINAI J. 
MED. 347, 348 (2000). 
53. See generally MEDICATION-ASSISTED TREATMENT FOR OPIOID 
ADDICTION, supra note 27, at 28. 
54. See id. 
55. Id. 
56. See id.  
57. See Herman et al., supra note 52, at 361. 
58. Hearing on Heroin and Prescription Drug Abuse, supra note 5. 
59. See id. 
60. See Herman et al., supra note 52, at 354. 
61. See 21 U.S.C. § 813. 
62. See 42 C.F.R. 8.12 (h)-(j). If the patient has continuously undergone 
methadone maintenance treatment for a period of time and has met the 
“take-home” eligibility criteria in the D.E.A. regulation, then the 
methadone clinic may permit him or her to take some methadone home.  
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centers are often heavily visible and stigmatized by city governments 
and residents.63 
B. Vivitrol  
Vivitrol is a medication for treating both opioid dependence and 
alcoholism.64  Vivitrol does not contain any opioid.65  Instead, it 
contains extended-release naltrexone, which is a complete mu-receptor 
antagonist, meaning it completely blocks the mu-receptor.66  As a 
result, Vivitrol prevents an individual from experiencing euphoria if 
he or she abuses any opioid,67 making the medication very effective at 
preventing opioid abuse relapse.68   
If a patient is given Vivitrol before an opioid has been naturally 
flushed out of his or her system, then the individual will experience 
immediate and painful withdrawals.69  As a result, opioid addicts must 
first detox completely before taking Vivitrol.70  
Vivitrol is not a controlled substance, so it can be prescribed by 
any physician.71  The medicine is taken as a once-per-month injection 
that lasts for 30 days.72  Unfortunately, it is very expensive, costing 
around $1,000 per month for an individual who lacks health insurance 
coverage,73 which is a common scenario for people suffering from 
substance abuse disorder.74 
 
The take-home amount ranges from one day’s worth to one month-
worth if the patient has been in treatment for at least two years Id. at 
8.12 (i)(3). 
63. See, e.g., Cherkis, supra note 16; Herman et al., supra note 52. 
64. See Adult Drug Courts and Medication-Assisted Treatment for Opioid 
Dependence, supra note 31, at 4-5; Substance Abuse & Mental Health 
Servs. Admin., An Introduction to Extended-Release Injectable 
Naltrexone for the Treatment of People with Opioid Dependence, 11 
ADVISORY (2012) [hereinafter An Introduction to Extended-Release 
Injectable Naltrexone], https://store.samhsa.gov/shin/content/SMA12-
4682/SMA12-4682.pdf. 
65. See id. 
66. See id. 
67. See Adult Drug Courts and Medication-Assisted Treatment for Opioid 
Dependence, supra note 31. 
68. See id. 
69. An Introduction to Extended-Release Injectable Naltrexone, supra note 
64. 
70. See id. 
71. See id. 
72. See id.  
73. See AM. ASS’N FOR THE TREATMENT OF OPIOID DEPENDENCE, AAOTD 
GUIDELINES FOR USING NALTREXONE (VIVITROL) IN OTPS (2015), 
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C. Buprenorphine 
Buprenorphine is a partial mu-agonist.75  As a partial mu-agonist, 
buprenorphine prevents the opioid-dependent individual from going 
into withdrawals or experiencing cravings.76  Unlike methadone, the 
opioid in buprenorphine is not very potent, so it is less likely to be 
abused and rarely causes an overdose.77  An individual taking 
buprenorphine can feel, act, and appear completely normal.78   
As a partial mu-antagonist, buprenorphine blocks the remainder 
of the mu-receptor, preventing a “high” from any additional opioid 
used (including too much buprenorphine).79  As a result, individuals 
who take buprenorphine daily have little incentive to abuse heroin, 
painkillers, or other opioids. 
Buprenorphine can be prescribed at any physician’s office, as long 
as the physician obeys Drug Enforcement Agency (DEA) rules for 
Schedule III substances, and provided that doctor has a waiver from 
the Substance Abuse and Mental Health Services Administration 
(SAMHSA), as required under the Drug Addiction and Treatment 
Act of 2000.80  An individual undergoing buprenorphine treatment 
typically receives a monthly prescription, which he or she fills at a 
local pharmacy, and then takes one or two pills or sublingual films at 
home daily.81  The DEA limits automatic refills on Schedule III 
narcotics to 5 refills or 6 months (whichever comes first).82  However, 
 
http://www.aatod.org/policies/policy-statements/aatod-guidelines-for-
using-naltrexone-vivitrol-in-otps/; Walter Armstrong, A Shot in the 
Dark: Can Vivitrol Help us Control Our Addictions, PAC. STANDARD 
MAG. (May 7, 2013), http://www.psmag.com/health-and-
behavior/vivitrol-help-control-addictions-57261. 
74. Approximately 25% of drug addicts lack health insurance.  See Health 
Care Overhaul Will Add Coverage for Millions of Addicts, CRAIN’S 
CHICAGO BUS. (Sept. 11, 2013), http://www.chicagobusiness.com/ 
article/20130911/NEWS03/130919947/health-care-overhaul-will-add-
coverage-for-millions-of-addicts. 
75. See generally About Buprenorphine Treatment, U.S. DEP’T OF HEALTH & 
HUMAN SERVS., http://buprenorphine.samhsa.gov/about.html. 
76. See id. 
77. See id. 
78. See U.S. DEP’T OF HEALTH & HUMAN SERVS., THE FACTS ABOUT 
BUPRENORPHINE FOR TREATMENT OF ADDICTION 3 (2011), 
http://store.samhsa.gov/shin/content/SMA09-4442/SMA09-4442.pdf. 
79. See id. 
80. See id. at 4.    
81. See About Buprenorphine Treatment, supra note 75. 
82. See 21 C.F.R. § 1306.22.  
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physicians commonly require patients on buprenorphine treatment to 
return monthly for an appointment to obtain a new prescription.83 
The effectiveness of buprenorphine at preventing relapse, 
euphoria, and drug cravings has been documented in numerous 
studies.84  When access to buprenorphine increases, mortality from 
opioid overdose decreases. 85   For example, in France, increased use of 
buprenorphine was associated with an 80% decrease in opioid 
overdoses.86  Additionally, buprenorphine lowers medical costs by 
preventing the need for expensive in-patient treatment or emergency 
room visits, increases employment among substance abusers, and 
reduces drug-related crimes.87  Buprenorphine has been used 
effectively and safely in opioid-dependent pregnant women88 and 
 
83. 15 Ways to Save Money on buprenorphine Treatment, NAT’L ALL. 
ADVOCATES FOR BUPRENORPHINE TREATMENT (Dec. 2014), 
http://www.naabt.org/buprenorphine-cost.cfm (“As the patient 
stabilizes, s/he can request to have less frequent office visits. Although 
physicians commonly require patients to come in for appointments every 
month to monitor the patient’s progress, schedule III medications can be 
refilled up to 5 times in a 6 month period.  Visit frequency is ultimately 
determined by the physician, but it doesn’t hurt to ask, particularly for 
those stable in long-term addiction remission and those who get therapy 
or counseling from other sources. Some states however, overrule the 
physician’s judgment and have set minimum periods between office 
visits.”). 
84. See Declan Barry et al., Integrating Buprenorphine Treatment into 
Office-based Practice: A Qualitative Study, 24 J. GEN. INTERN. MED. 
218, 219 (2009). 
85. See CDC, Buprenorphine Prescribing Practices and Exposures Reported 
to a Poison Center –Utah 2002-2011, 61 MORBIDITY & MORTALITY 
WEEKLY REPORT 997, 997 (Dec. 14, 2012) [hereinafter CDC, 
Buprenorphine Prescribing Practices], http://www.cdc.gov/mmwr/ 
preview/mmwrhtml/mm6149a1.htm (“In France, widespread use of 
medication-assisted therapy, primarily buprenorphine treatment, was 
associated with an 80% decrease in overdose deaths from heroin or 
cocaine from 465 in 1996 to 89 in 2003”). See also Julien Emmanuelli & 
Jean-Claude Desenclos, Harm reduction interventions, behaviours and 
associated health outcomes in France, 1996–2003, 100 ADDICTION 1690 
(2005). 
86. See CDC, Buprenorphine Prescribing Practices, supra note 85. 
87. See generally Amine Khemiri et al., Analysis Of 
Buprenorphine/Nalexone Dosing Impact on Treatment Duration, 
Resource Use, and Costs in the Treatment of Opioid Dependent Adults: 
A Retrospective Study of U.S. Public and Private Health Care Claims, 
126 POSTGRADUATE MED. J. 113 (2014).  
88. See Lori Whitten, Buprenorphine During Pregnancy Reduces Neonate 
Distress, NAT’L INST. ON DRUG ABUSE (July 6, 2012), 
http://www.drugabuse.gov/news/events/nidanotes/2012/07/buprenorph
ine-during-pregnancy-reduces-neonate-distress. 
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adolescents.89  As the dose of buprenorphine and length of treatment 
increases, the risk of relapse decreases.90  Buprenorphine increases 
compliance with mental health therapy regimens.91  Individuals 
undergoing buprenorphine treatment are more likely to actively 
participate regularly in out-patient mental health counseling than 
individuals who are not undergoing buprenorphine treatment.92 
Individuals may have an easier time focusing on behavioral and 
psychological changes if their physical symptoms are controlled.   
In 2008, buprenorphine prescriptions cost about $120-$570 per 
month (depending on the dose) without health insurance.93  However, 
the FDA recently approved two generic versions of Suboxone 
(buprenorphine-nalexone), so the cost of buprenorphine prescriptions 
for patients may have decreased.94  Commercial health insurance 
carriers95 and state Medicaid programs cover buprenorphine treatment 
(although some Medicaid programs have coverage time limits)96.  
Some pharmaceutical companies that manufacture buprenorphine 
 
89. See Lori Whitten, Youth Opioid Abusers Benefit from Extended 
Buprenorphine-Nalexone Treatment, NAT’L INST. ON DRUG ABUSE (April 
1, 2010), http://www.drugabuse.gov/news-events/nida-
notes/2010/04/young-opioid-abusers-benefit-extended-buprenorphine-
naloxone-treatment. 
90. See George E. Woody et al., Extended vs Short-Term Buprenorphine-
Naloxone for Treatment of Opioid-Addicted Youth: A Randomized 
Trial, 300 JAMA 2003, 2007 (2008). 
91. See Ryan Caldiero et al., Inpatient Initiation of Buprenorphine 
Maintenance vs. Detoxification: Can Retention of Opioid-Dependent 
Patients in Outpatient Counseling be Improved?, 15 AM. J. ON 
ADDICTIONS 1, 4-6 (2006) (maintenance treatment on buprenorphine 
leads to higher retention in outpatient counseling than detoxification 
treatment only). 
92. See id. at 4-5. 
93. See Lynn E. Sullivan & David A. Fiellin, Office-Based Buprenorphine 
for Patients with Opioid Dependence, 148 ANNALS OF INTERNAL MED. 
662, 667 (2008). 
94. See Paul Jarvis & Matthew Boyle, Reckitt Benckiser Faces Generic 
Threats after FDA Rejection, BLOOMBERG BUS. (Feb. 25, 2013), 
http://www.bloomberg.com/news/articles/2013-02-25/reckitt-benckiser-
says-fda-rejects-suboxone-safeguard-petition. 
95. See Does Insurance Cover It?, NAT’L ALL. ADVOCATES FOR 
BUPRENORPHINE TREATMENT (Dec. 2008), 
http://www.naabt.org/faq_answers.cfm?ID=37.  
96. See Robin Clark et al., The Evidence Doesn’t Justify Steps By State 
Medicaid Programs to Restrict Opioid Addiction Treatment with 
Buprenorphine, 30 HEALTH AFF. 1425, 1425 (2011). 
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provide discount cards for low-income individuals, which may 
eliminate some of the prescription cost.97 
Probuphine, a slow-release, surgical implant of buprenorphine 
completed stage III clinical trials in 2015.  In January 2016, the 
Psychopharmacologic Drugs Advisory Committee of the FDA 
recommended approval of Probuphine.98  If approved by the FDA, 
Probuphine would eliminate the need for frequent doctor visits 
because the implant would last for 6 months at a time.99  The implant 
would also eliminate the potential for diversion.100  It is unclear how 
and whether current regulations on buprenorphine prescriptions would 
apply to Probuphine, if approved. 
D. Buprenorphine versus Vivitrol 
Benefits of buprenorphine relative to Vivitrol include the 
following.  Unlike Vivitrol, buprenorphine treatment does not require 
complete detoxification prior to the first dose.101  Rather, 
buprenorphine treatment begins when the patient is in mid-
withdrawal.102  For many opioid-dependent individuals, the need to 
completely physically detoxify prior to treatment may act as a 
disincentive to beginning treatment.  Opioid withdrawals are very 
painful and commonly include multiple days (sometimes weeks) of 
diarrhea, muscle aches, excessive sweating, jerking or twitching 
 
97. See, e.g., Savings Card May Help Reduce Costs Each Month for Eligible 
Patients, SUBOXONE (2014), http://www.suboxone.com/hcp/savings-
card. 
98. See Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce 
FDA Advisory Committee Recommends Approval of Probuphine, First 
6-Month Implant to Treat Opioid Addiction, Braeburn Pharmaceuticals 
(Jan. 12, 2016), https://braeburnpharmaceuticals.com/titan-
pharmaceuticals-and-braeburn-pharmaceuticals-announce-fda-advisory-
committee-recommends-approval-of-probuphine-first-6-month-implant-
to-treat-opioid-addiction/; Sabrina Tavernise, Implant for Opioid 
Addicts Urged for Federal Approval, New York Times (Jan. 12, 2016), 
http://www.nytimes.com/2016/01/13/health/implant-for-opioid-addicts-
urged-for-federal-approval.html?_r=0. 
99. Id. 
100. Id. 
101. For information regarding beginning buprenorphine, see Kathleen 
Thompson-Gargano, What is Buprenorphine Treatment Like?, NAT’L 
ALL. ADVOCATES FOR BUPRENORPHINE TREATMENT, 
http://www.naabt.org/education/what_bt_like.cfm.  For information 
regarding beginning Vivitrol, see An Introduction to Extended-Release 
Injectable Naltrexone, supra note 64. 
102. See What is Buprenorphine Treatment Like?, supra note 101. 
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muscles, fatigue, and nausea.103  Complete detoxification from opioids 
without relapse is extremely difficult, often requiring multiple 
attempts.  As a result, individuals sometimes enroll in in-patient 
rehabilitation centers in order to detox, which cost approximately 
$31,500 for 30 days.104   
Buprenorphine is significantly less expensive than Vivitrol.  
Brand-name buprenorphine costs approximately $120-$570 per month 
without health insurance,105 whereas Vivitrol costs about $1000 per 
month without health insurance.106  Also, whereas a patient may 
obtain up to five automatic refills of buprenorphine without returning 
to the physician’s office,107 Vivitrol requires a monthly visit to a 
physician.108  Therefore, aggregate costs associated with physician 
visits may be higher for a patient treated with Vivitrol. 
There are some benefits of Vivitrol relative to buprenorphine.  
First, unlike buprenorphine, Vivitrol is not a controlled substance, so 
any physician may legally prescribe it.109  Therefore, it may be easier 
for patients to find a physician prescribing Vivitrol than a physician 
prescribing buprenorphine.110  Second, because Vivitrol is a once-per-
month injection, patients may find it easier to adhere to Vivitrol 
treatment.  On the other hand, patients could simply stop taking 
buprenorphine on any day of the month, because it is a daily pill or 
sublingual film.111  Finally, because Vivitrol contains no opioid 
ingredient, it is practically impossible to abuse or overdose on 
Vivitrol.112   
E. Buprenorphine versus Methadone 
Buprenorphine treatment has several advantages relative to 
methadone treatment for opioid addiction. First, buprenorphine is less 
likely to be abused than methadone, because it is a partial mu-agonist 
 
103. See What is withdrawal?, NAT’L ALL. ADVOCATES FOR BUPRENORPHINE 
TREATMENT (2008), http://www.naabt.org/faq_answers.cfm?ID=16. 
104. See Cherkis, supra note 16. 
105. See Sullivan & Fiellin, supra note 93, at 667. 
106. See AM. ASS’N FOR THE TREATMENT OF OPIOID DEPENDENCE, supra note 
73; Armstrong, supra note 73. 
107. See 21 C.F.R. § 1306.22. 
108. See An Introduction to Extended-Release Injectable Naltrexone, supra 
note 64. 
109. See id. 
110. For legal restrictions on prescribing buprenorphine, see supra Part IV. 
111. See id. 
112. See id. 
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rather than a complete mu-agonist.113  The opioid ingredient in 
buprenorphine is less potent than the opioid ingredient in 
methadone.114  As a result, far fewer emergency room visits have been 
reported from buprenorphine abuse than from methadone abuse.115   
As compared to methadone, buprenorphine may have less cultural 
stigma attached to it, because buprenorphine can be prescribed in a 
physician’s office and taken at home daily, potentially making 
buprenorphine seem like any other medicine.116  Furthermore, because 
buprenorphine may be prescribed by primary care doctors, 
appointments for buprenorphine treatment seem more anonymous 
than visiting a methadone clinic.117  For example, if a person 
undergoing buprenorphine treatment is seen entering a primary care 
doctor’s office by a co-worker, then the co-worker has no way of 
knowing the reason for the visit.  On the other hand, entering a 
methadone clinic is a sure sign of being drug-dependent.   
Finally, buprenorphine treatment is less time-consuming than 
methadone treatment, because a thirty-day supply of buprenorphine 
can be obtained from a local pharmacy and then taken at home 
daily.118  On the other hand, methadone treatment generally requires 
daily travel-time to a methadone clinic.119  Many individuals suffering 
from substance abuse are low-income individuals120 for whom it may 
 
113. See About Buprenorphine Treatment, supra note 75 (“Because of its 
ceiling effect and poor bioavailability, buprenorphine is safer in overdose 
than opioid full agonists. The maximal effects of buprenorphine appear 
to occur in the 16–32 mg dose range for sublingual tablets. Higher doses 
are unlikely to produce greater effects.”). 
114. See id. 
115. See id. 
116. See Hayley Pinto et al., The SUMMIT Trial: A Field Comparison of 
Buprenorphine vs. Methadone Treatment, 39 J. SUBSTANCE ABUSE 
TREATMENT 340 (2010). 
117. See id.  See also Alison Knopf, Hoffman Death Shows Need for 
Methadone and Buprenorphine.  ALCOHOLISM & DRUG ABUSE WEEKLY 1, 
2-3 (Feb. 10, 2014), http://www.alcoholismdrugabuseweekly.com/m-
article-detail/hoffman-death-shows-need-for-methadone-and-
buprenorphine.aspx. 
118. See generally MEDICATION-ASSISTED TREATMENT FOR OPIOID 
ADDICTION, supra note 27; Stotts et al., supra note 27; A.Y. Walley et 
al., Methadone Dose, Take Home Status and Hospital Admission among 
Methadone Maintenance Patients, 6 J. ADDICTION MED. 186 (2002).   
119. See id. 
120. See Frank Chaloupka et al., Introduction, in THE ECONOMIC ANALYSIS 
OF SUBSTANCE USE AND ABUSE: AN INTEGRATION OF ECONOMETRICS AND 
BEHAVIORAL ECONOMIC RESEARCH 10 (Frank Chaloupka et al. eds., 
1999). 
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be especially difficult to pay for daily transportation to a methadone 
clinic or to take time off of work to visit a clinic. 
III. Existing Buprenorphine Regulations 
A. Drug Enforcement Agency Scheduling 
Under the Controlled Substances Act (CSA), Congress delegates 
authority to the Attorney General to place substances or drugs within 
five schedules of control, with Schedule V being the least restrictive 
and Schedule I being the most restrictive.121   For example, heroin is 
in Schedule I and oxycodone is in Schedule II.122  The Attorney 
General’s decision must be based on the substance’s abuse potential, 
medical value, safety, and potential for dependency. 123  In making 
findings about abuse potential, the Attorney General must consider 
the following factors regarding the substance: actual or relative 
potential for abuse; scientific evidence of its pharmacological effect; 
current scientific knowledge; history and current pattern of abuse; 
scope, duration, and significance of abuse; risks to public health; 
psychic or physiological dependence liability; and whether it is an 
immediate precursor of a substance already scheduled under the 
CSA.124 The Attorney General must consult with the Secretary of 
Health and Human Services before scheduling the substance.  If the 
Secretary recommends against controlling the drug, then the Attorney 
General must honor that decision.  Finally, rules must be made on the 
record and adhere to rule making requirements under 5 U.S.C.S. § 
551.125 
In 1981, the FDA approved the first version of buprenorphine as 
an injectable, hospital-based pain killer.126  In 1985, the Drug 
Enforcement Agency (DEA) scheduled that version of buprenorphine 
as a Schedule V narcotic under the CSA.127  Schedule V controlled 
substances have the following characteristics: a lower potential for 
abuse than substances in Schedule IV; a currently accepted medical 
use in treatment in the U.S.; and limited potential of physical 
 
121. See 21 U.S.C. § 812. 
122. See id.  
123. See 21 U.S.C. § 811(a)(1). 
124. See id. 
125. See id. 
126. See Schedules of Controlled Substances, 67 Fed. Reg. 62354, 62354 
(codified at 21 C.F.R. pt. 1308) (Oct. 7, 2002). 
127. Schedules of Controlled Substances, 50 Fed. Reg. 8104 (Feb. 28, 1985). 
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dependence or psychological dependence relative to substances in 
Schedule IV.128 
In 2002, after other countries (especially France) had successful 
experiences with buprenorphine for treating opioid dependence,129 the 
FDA approved buprenorphine for treating opioid dependence under 
the brand names Suboxone and Subutex.130  Suboxone contains an 
abuse-deterrent ingredient, nalexone, which causes immediate 
withdrawals if the medication is abused by intravenous injection.131  
Therefore, Suboxone is even less likely to be abused than Subutex or 
plain buprenorphine.132   
Aware that buprenorphine would shortly be approved by the 
FDA for addiction treatment, in 2002 the DEA rescheduled 
buprenorphine from Schedule V to Schedule III of the CSA (following 
a recommendation from the Department of Health and Human 
Services).133  Under the CSA, substances in Schedule III have the 
following characteristics: a lower potential for abuse than substances 
in Schedules I and II; a currently accepted medical use in treatment 
in the U.S.; and the potential for moderate or low physical 
dependence or high psychological dependence.134 
According to the National Alliance of Advocates for 
Buprenorphine Treatment, the DEA rescheduled buprenorphine 
despite “overwhelming objection from the medical community,” which 
was concerned that more restrictive scheduling would cause 
accessibility problems.135 The American Academy of Addiction 
Psychiatry and the American Association of Addiction Medicine both 
recommended less restrictive scheduling for Suboxone, especially 
because it contains naloxone.136   
 
128. See 21 U.S.C. § 812 (b)(5). 
129. See CDC, Buprenorphine Prescribing Practices, supra note 85. See also 
Emmanuelli & Desenclos, supra note 85, at 1696. 
130. Subutex and Suboxone Approved to Treat Opiate Dependence, U.S. 
FOOD & DRUG ADMIN. (Oct. 8, 2012), 
http://www.fda.gov/Drugs/DrugSafety/ 
PostmarketDrugSafetyInformationforPatientsandProviders/ucm191521.h
tm. 
131. See 67 Fed. Reg. 62354, 62358 (Oct. 7, 2002). 
132. See id. 
133. See id. at 62354. 
134. See 21 U.S.C. § 812 (b)(3). 
135. Laws, NAT’L ALL. ADVOCATES FOR BUPRENORPHINE TREATMENT (Oct. 
29, 2013), http://www.naabt.org/laws.cfm. 
136. See generally 67 Fed. Reg. 62354, 62355 (Oct. 7, 2002). 
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In its determination of buprenorphine’s abuse potential, the DEA 
considered the fact that buprenorphine would be prescribed to 
“known drug abusers.”137  In its response to comments on the Final 
Rule addressing rescheduling, the DEA wrote, “Simply stated, 
providing an abusable substance to known drug abusers imparts 
enhanced risks [sic].”138   
The DEA also feared that buprenorphine would be illicitly 
obtained by the opioid naïve (new users) or by “non-dependent, 
opioid-experienced subjects”.139  The DEA found that such individuals 
may feel “good drug effects”140 if they try to abuse buprenorphine.  
Ironically, opioid-dependent individuals rarely feel any “good drug 
effects” from buprenorphine.141  Instead, they feel normal when 
treated with buprenorphine.142 
By rescheduling buprenorphine, the DEA appeared to be more 
concerned with buprenorphine’s potential to harm opioid naïve and 
non-opioid-dependent individuals than with its potential benefits to 
opioid-dependent individuals.143  In its response to comments on the 
Final Rule, the DEA stated that “buprenorphine has abuse potential 
in a wide spectrum of individuals.  Vulnerable populations include 
drug naïve individuals (new drug abusers), opioid experienced 
individuals and opioid dependent individuals.”144  However, later the 
DEA stated that, “The extent to which buprenorphine is able to 
produce euphoria and “good drug” effects limits its use by opioid 
tolerant abusers.”145   
The DEA did not worry much about the impact of rescheduling 
buprenorphine on access to treatment.146  In response to a comment 
that rescheduling buprenorphine would make it less accessible for 
dependent individuals who need buprenorphine for treatment, the 
DEA said the following:  
 
137. Id. at 62357. 
138. Id. 
139. Id. at 62358. 
140. Id. 
141. See id. 
142. See The Facts about Buprenorphine for Treatment of Opioid Addiction, 
supra note 78, at 3; Medication proponents make pitch to drug court 
professionals, 16 ALCOHOLISM & DRUG ABUSE WEEKLY 2 (Aug. 16, 
2004). 
143. See 67 Fed. Reg. 62354, 62357-62358. 
144. Id.at 62357. 
145. Id. at 62359. 
146. See id. at 62363. 
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The proposed placement of buprenorphine in Schedule III was 
not made on the basis of making buprenorphine products 
available for office-based narcotic treatment…The DEA did not 
consider the need to expand narcotic treatment as a specific 
factor in determining the placement of buprenorphine under the 
CSA.147  
The more restrictive the scheduling, the less accessible the 
medication becomes.  All physicians who prescribe controlled 
substances must register with the DEA, obtain a DEA number, and 
meet DEA reporting requirements.148  However, under the CSA 
physicians may only prescribe automatic refills for Schedule III 
narcotics for up to six months or five prescriptions (whichever is 
first).149  On the other hand, there are no automatic prescription 
limitations for prescribing Schedule V substances.150  Also, the more 
restrictive the scheduling, the less likely physicians may be to 
prescribe the medication out of fear of losing their medical license for 
wrong-doing.151 
B. Drug Addiction and Treatment Act of 2000 
Foreseeing the likely FDA approval of buprenorphine, Congress 
passed the Drug Addiction and Treatment Act (DATA) in 2000.  
DATA modified the CSA,152 permitting physicians to prescribe 
Schedule III, IV, and V substances for addiction treatment, while 
trying to prevent its diversion and abuse.153   
 
147. Id. 
148. See 21 U.S.C. § 823 (g). 
149. See 21 C.F.R. § 1306.22. 
150. See id. 
151. See Rob Stein, Painkiller Paradox: Feds Struggle to Control Drugs that 
Help and Harm, NPR (Jan. 23, 2013), 
http://www.npr.org/blogs/health/2013/01/23/169963431/painkiller-
paradox-feds-struggle-to-control-drugs-that-help-and-harm. 
152. See 21 U.S.C. § 823(g). 
153. See Drug Addiction Treatment Act of 2000, 146 CONG. REC. H6374-
H6375 (Rep. Gilman said the following: “[The legislation] seeks to assist 
qualified physicians in treating their addicted patients, to speed up 
approval of narcotic drugs for addiction treatment purposes, and 
offers treatment options for those Americans for whom 
other treatment programs are financially out of reach…The bill contains 
a number of safeguards that are designed to prevent abuses of the 
waiver procedure.” Id. at H6377).  The Drug Addiction Treatment Act 
was ultimately passed by Congress as Title XXXV, Section 3502 of the 
Children’s Health Act of 2000. 
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DATA was passed by Congress with little controversy.  The 
initial version of the Act, DATA of 1999, was introduced by Senator 
Hatch (R) in the Senate but was never voted upon.154  Representative 
Biley (R) then re-introduced DATA in the House of Representatives 
with Republican and Democratic co-sponsors as DATA of 2000.155  It 
easily passed in the House with 412 “yea” votes and only one “nay” 
vote.156  The Senate then added DATA of 2000 as an amendment to 
the Children’s Health Act of 2000.157  The Senate approved this 
version of the Children’s Health Act unanimously.  The revised 
Children’s Health Act returned to the House for a final vote, where it 
was passed by a large majority158 with DATA as Title XXXV.159 
DATA became law two years prior to the DEA rescheduling 
buprenorphine from Schedule V to Schedule III of the CSA.  The 
DEA was aware of DATA and its purpose.  However, in its Final 
Rule the DEA stated that it was not considering how rescheduling 
buprenorphine would impact the objectives of DATA: “The Drug 
Addiction Treatment Act (DATA) does not have an impact on 
DEA’s scheduling responsibilities under the CSA.”160 
DATA requires physicians to obtain a waiver (colloquially called 
a DATA waiver or SAHMSA waiver) from the Secretary of Health 
and Human Services. 161   In order to obtain a waiver, the physician 
must submit a notification of intent to the Secretary to begin 
prescribing such medications to the Secretary.  This notification must 
demonstrate that the physician meets the following requirements 
 
154. Drug Addiction Treatment Act of 1999, S. 324, 106th Congress (1999). 
155. Drug Addiction Treatment Act of 2000, H.R. 2634, 106th Congress 
(2000).  Representative Bliley (R) was the main sponsor, with the 
following co-sponsors: Boucher (D), Green (D), Rangel (D), Norwood 
(R), Upton (R), Coble (R), Greenwood (R), Deal (R), Cox (R), and 
Oxley (R). 
156. See Final Vote Results for Roll Call 416 (Drug Addiction Treatment 
Act of 2000), OFFICE OF THE CLERK OF THE U.S. HOUSE OF 
REPRESENTATIVES (July 19, 2000).  
http://clerk.house.gov/evs/2000/roll416.xml.  
157. See S.Amdt. 4181 to H.R.4365, 106th Congress (2000).  
158. See Final Vote Results for Roll Call 496 (Children’s Health Act of 
2000), OFFICE OF THE CLERK OF THE U.S. HOUSE OF REPRESENTATIVES 
(Sep. 27, 2000), http://clerk.house.gov/evs/2000/roll496.xml. There 
were 394 Yea votes and 25 Nay votes. 
159. Children’s Health Act of 2000, Pub. L. No. 106-310, § 3502, (codified 
at (g) (2006 )). 
160. See Schedules of Controlled Substances, 67 Fed. Reg. 62354, 62366 (Oct. 
7, 2002). 
161. See id. at § 823 (g)(2)(A). 
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under DATA: 1) the physician is “qualified” to prescribe medication 
for opioid dependence treatment; 2) the physician will adhere to the 
patient limits in DATA; and 3) the physician has the capacity to refer 
patients for ancillary mental health services.162  DATA’s definition of 
“qualified physician” and patient limits are described below. 
1. Qualified Physicians 
A physician becomes “qualified” by meeting the requirements in 
section 2(a)(5)(G) of DATA.  First, the physician must have a valid 
medical license under state law.163   
Second, the physician must prove that he or she has the necessary 
education or experience to treat opioid-dependent individuals with 
buprenorphine (and similar medicines).  The physician may 
demonstrate the education/experience requirement in any one of the 
following ways:  
(a) by having been awarded board certification as an addiction 
specialist (by a major medical authority listed in the statute); or 
(b) by completing an addiction medicine educational course at 
least 8 hours in length (provided by a medical authority listed 
in the statute); or 
(c) by participating as a principal investigator in a drug trial for 
buprenorphine or a similar medication; or 
(d) by otherwise convincing the state’s medical board or the 
U.S. Secretary of Health that the physician has valid 
experience/education for treating opioid-dependent patients.164   
Physician assistants and nurse practitioners cannot become 
qualified (cannot obtain a DATA waiver), even if they are licensed in 
a state that permits physician assistants and nurse practitioners to 
prescribe Schedule III, IV, or V medications.165   
2. Patient Limits 
In addition to defining who constitutes a “qualified physician” for 
purposes of obtaining a DATA waiver, DATA also places restrictions 
on the number of patients a qualified physician may treat at any one 
time.166  These patient restrictions have been widely criticized within 
 
162. Id.  
163. Id. 
164. Id. at § 823 (g)(2)(B)(iii). 
165. See id. at § 823 (g)(2)(G).  
166. See id. at § 823 (g)(2)(B)(iii). 
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the medical community.167  Since the passage of DATA, Congress has 
twice amended the patient restrictions in order to expand the number 
of patients a physician may treat.168 
a. Original Patient Limits 
The original DATA Act prohibited any physician from treating 
more than thirty patients with buprenorphine at any time. 169  The 
original DATA Act also prohibited a group practice of physicians 
from treating more than thirty patients with buprenorphine at any 
time. 170  In other words, if three physicians owned a group practice 
and one of those physicians was treating thirty patients with 
buprenorphine, then the other two physicians could not treat any 
patients with buprenorphine.   
b. 2005 Amendment 
In 2005, Congress passed the Drug Addiction Treatment 
Expansion Act, which amended DATA by eliminating the thirty 
patient limit on group practices, but leaving the thirty patient limit 
in place for each qualified physician.171  Under this law, if three 
physicians owned a group practice, then each physician within the 
group could treat up to thirty patients at any time with 
buprenorphine.172   
The legislative history of the Drug Addiction Treatment 
Expansion Act demonstrates that Congress was concerned with the 
negative effects that the group prescription limit had on patient 
access.  Rep. Mark Souder made the following statement regarding 
the need for the Drug Addiction Treatment Expansion Act: 
 
167. See, e.g., ASAM Letter, supra note 43 (“We have at our disposal highly 
effective, FDA-approved pharmacotherapies to treat opioid addiction. 
Unfortunately, they all come with arbitrary treatment limits that have 
resoundingly negative effects on treatment access and outcomes.”); 
MEDICATION-ASSISTED TREATMENT FOR OPIOID ADDICTION, supra note 
27, at 4-5 (noting that a National Institute of Health consensus panel 
has called for less restrictions on medication for treating addiction). 
168. See Drug Addiction Treatment Expansion Act, 151 CONG. REC. D877 
(daily ed. Sept. 6, 2005); Office of National Drug Control Policy 
Reauthorization Act of 2006, Public L. 109-469 (2006) (codified at 21 
U.S.C. § 1701, et seq.) 
169. See Drug Addiction Treatment Act of 2000, 21 U.S.C. § 823 
(g)(2)(B)(iii). 
170. See id. 
171. See Drug Addiction Treatment Expansion Act, 21 U.S.C. § 823 
(g)(2)(B). 
172. See id. 
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According to the American Medical Association, the current 30-
patient cap has limited access to effective substance abuse 
treatment services…Lifting the cap would enable group practices 
to treat more patients with this highly effective drug.173 
c. 2006 Amendment 
In 2006, due to growing demand for buprenorphine and long wait 
times to see qualified physicians, Congress passed the Office of 
National Drug Control Policy Reauthorization Act.174   This is the 
current law with respect to patient limits.  Title XI of the Act 
permits physicians who have had a DATA waiver for at least one year 
to treat up to 100 patients beginning the second year, after notifying 
the Health Secretary of their intent to treat 100 patients.175  When the 
Act passed, Sen. Orin Hatch made a congratulatory speech: 
It is clear this [30 patient] cap needs to be raised.  To make an 
analogy, a doctor who would not turn away a broken arm 
because he or she had already fixed 30 arms that month!  The 
doctor would not stand for it, and neither would society.  The 
same should be true for physicians treating drug addiction.  
Given that the destructive effects of drug addiction are so much 
greater than a broken arm, we should strive to ensure that the 
healing hands of doctors are not bound by unintended 
mandates.176  
IV. Underuse of Buprenorphine 
Despite buprenorphine’s benefits, it is still underutilized.  The 
U.S. Substance Abuse and Mental Health Services Administration,177 
the American Medical Association,178 the American Society of 
 
173. 151 CONG. REC. H6679-H6681 (daily ed. July 27, 2005) (Statement of 
Rep. Souder). 
174. See Office of National Drug Control Policy Reauthorization Act of 2006, 
Public L. 109-469 (2006). 
175. See id. 
176. 152 CONG. REC. S11703-S11706 (daily ed. Dec. 8, 2006) (statement of 
Sen. Orin Hatch). 
177. See, e.g., Adult Drug Courts and Medication-Assisted Treatment for 
Opioid Dependence, supra note 31. 
178. Statement of the American Medical Association to the Committee on 
Energy & Commerce Subcommittee on Oversight and Investigations, 
U.S. House of Representatives at 6, (April 23, 2015), 
http://docs.house.gov/meetings/IF/IF02/20150423/103367/HHRG-114-
IF02-Wstate-HarrisP-20150423.pdf. 
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Addiction Medicine,179 and the World Health Organization180 all agree 
that buprenorphine treatment should be more widely used to treat 
opioid addiction.  In order to encourage utilization of buprenorphine 
for addiction treatment, policy makers should address reasons for its 
underuse.  Scholars have reported the following reasons for underuse: 
cultural bias against MAT (medication assisted treatment for drug 
dependence); bias from NA and other 12-step groups; bias among 
mental health therapists; an undersupply of physicians with a DATA 
waiver; patient limits under DATA; cost; and concerns of illicit 
diversion.   
A. Cultural Bias Against MAT 
The U.S. has an unusual cultural bias against the use of FDA-
approved medication for treating drug dependence,181 especially given 
the fact that medication is commonly used to treat other illnesses.  
Americans consider pharmaceuticals to be a normal part of life, as the 
frequency of television advertisements for pharmaceuticals 
demonstrates.  Then, why is medication for treating drug dependence 
so heavily stigmatized?   
Bias against MAT likely stems from America’s historical 
paradigm of treatment for drug dependence, which has been 
“abstinence-only” (usually meaning without medications containing 
an opioid ingredient).  Today, abstinence-only treatment is the norm 
in the U.S. and is deeply entrenched in U.S. culture.182  Abstinence-
only treatment is espoused by NA, AA and other twelve-step 
groups.183  Twelve-step programs are the predominant form of 
treatment within U.S. prisons, drug courts, and in-patient 
rehabilitation centers.184  NA also has a powerful influence on the 
treatment methods of many mental health counselors.185  Therefore, to 
 
179. ASAM Letter, supra note 43 (“We have at our disposal highly effective, 
FDA-approved pharmacotherapies to treat opioid addiction. 
Unfortunately, they all come with arbitrary treatment limits that have 
resoundingly negative effects on treatment access and outcomes.”) 
180. See WHO Model List of Essential Medicines, supra note 40; 
WHO/UNODC/UNAIDS POSITION PAPER: SUBSTITUTION MAINTENANCE 
THERAPY, supra note 41. 
181. See generally MEDICATION-ASSISTED TREATMENT FOR OPIOID 
ADDICTION, supra note 27, at 8-10. 
182. See Cherkis, supra note 16. 
183. See id. 
184. See id.; Emily Galas, Endorsing Religion: Drug Courts and the 12-Step 
Recovery Support Program, 53 AM. U. L. REV. 1063, 1070 (2004); Nunn 
et al., supra note 31, at 87. 
Health Matrix·Volume 26·Issue 1·2016 
America Needs the TREAT Act:  
Expanding Access to Effective Medication for Treating Addiction 
336 
understand America’s attitudes towards drug dependence treatment, 
one must understand the philosophy of NA. 
NA is a derivative of AA and operates in an identical manner to 
AA, except that members of NA are usually drug-dependent, while 
members of AA are alcohol-dependent.  In brief, members of NA 
attend group meetings regularly, follow twelve steps of treatment, and 
receive emotional support and guidance from a sponsor within the 
group.186  AA originated from an evangelical, Protestant church in the 
1930s called the Oxford Group.187  Bill W., a member of the Oxford 
Group started AA to share with others the way he became sober. He 
became sober after a spiritual experience,188 which convinced him that 
any chemical-dependent individual can overcome his or her 
dependence through a similar spiritual experience.  He believed that 
sobriety can be achieved if the individuals shifts his or her dependence 
away from chemicals and towards a Higher Power.189  He also believed 
that chemical-dependent individuals (mainly alcoholics) must support 
each other on their journey of recovery through fellowship meetings.190  
Based off of these principles, Bill W. developed the following 12 steps 
(adopted by NA) that one must undergo in order to recover from 
chemical dependence:191   
1. We admitted that we were powerless over our addiction, that 
our lives had become unmanageable. 
2. We came to believe that a Power greater than ourselves could 
restore us to sanity. 
3. We made a decision to turn our will and our lives over to the 
care of God as we understood Him.  
 
185. See Traci Rieckmann et al., A Multi-level Analysis of Counselor 
Attitudes Toward the use of Buprenorphine in Substance Abuse 
Treatment, 41 J. OF SUBSTANCE ABUSE TREATMENT 374 (2011). See also 
Hannah Knudsen et al.,  Buprenorphine Diffusion: The Attitudes of 
Substance Abuse Treatment Counselors, 29 J. SUBSTANCE ABUSE 
TREATMENT 95 (2005).   
186. See generally Galas, supra note 184. 
187. See id. at 1073. 
188. See id.  
189. See id. at 1074. 
190. See id. at 1074-75. 
191. How it Works, NARCOTICS ANONYMOUS, http://www.na.org/admin/ 
include/spaw2/uploads/pdf/litfiles/us_english/misc/How%20it%20Wor
ks.pdf.  
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4. We made a searching and fearless moral inventory of 
ourselves. 
5. We admitted to God, to ourselves, and to another human 
being the exact nature of our wrongs. 
6. We were entirely ready to have God remove all these defects 
of character. 
7. We humbly asked Him to remove our shortcomings. 
8. We made a list of all persons we had harmed and became 
willing to make amends to them all. 
9. We made direct amends to such people wherever possible, 
except when to do so would injure them or others. 
10. We continued to take personal inventory and when we were 
wrong promptly admitted it. 
11. We sought through prayer and meditation to improve our 
conscious contact with God as we understood Him, praying only 
for knowledge of His will for us and the power to carry that out. 
12. Having had a spiritual awakening as a result of these steps, 
we tried to carry this message to addicts, and to practice these 
principles in all our affairs.192 
The twelve steps have the following themes: regular 
communication with the group, dependence on a Higher Power, 
striving for moral purity, seeking forgiveness, helping others stay 
drug-free, and admitting the nature of one’s problem.193  NA and AA 
identify alcoholism and drug dependence as a disease, not as a moral 
failing, but the treatment hinges on spiritual and moral steps.194  
Medication, on the other hand, is unrelated to spiritual healing, and 
thus does not fit neatly into the discourse of NA or AA.   
Even though most Americans are not dependent on opioids and 
have little education about its treatment, many Americans assume 
that NA/AA or a similar twelve-step group is the best treatment for 
opioid dependence.195  The belief is so common that it even pervades 
 
192. See id. 
193. See id. 
194. See id. 
195. See generally Cherkis, supra note 16. 
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offices of some health care practitioners.196 For example, most in-
patient rehabilitation centers197 and a large minority of mental health 
counselors believe that NA/AA alone or with counseling is the best 
form of treatment for opioid dependence.198   This belief has also 
infiltrated the criminal justice system.  Drug courts routinely require 
that drug offenders attend an NA or AA meeting daily,199 but only 
half allow the use of MAT.200  Likewise, few prison clinics offer 
MAT.201 
Within the cultural context of NA, medication for treating drug 
dependence does not sit well with the abstinence-oriented ideas of 
many Americans.202  Additionally, the provision of medication that 
contains an opioid ingredient to known drug abusers strikes some 
Americans as being “immoral,” despite the medications’ effectiveness 
at lowering crime rates, mortality, morbidity, and medical costs.  For 
example, despite the proven benefits of methadone, in the 1990s New 
York City then-Mayor Rudy Guiliani called methadone treatment an 
“immoral solution” to opioid dependence.203   
Many Americans assume that drug dependence is caused by being 
an immoral person.204  Therefore, treating dependence seems to require 
the provision of morality, not medication.  NA fits comfortably within 
this idea of morality-induced abstinence. Even though NA officially 
calls addiction a disease, NA requires the addict to seek forgiveness, 
to strive for moral purity, and to forge a relationship with a Higher 
Power.205  Obtaining a prescription for medication from a physician, 
 
196. See John F. Kelly, Self-Help for Substance-Use Disorders: History, 
Effectiveness, Knowledge Gaps, and Research Opportunities, 23 
CLINICAL PSYCHOLOGY REV. 639, 642-43 (2003). 
197. See, e.g., Cherkis, supra note 16. 
198. See Knudsen et al., supra note 185, at 98.   
199. See, e.g., Jennifer Murphy, Drug Court as Both a Legal and Medical 
Authority, 32 DEVIANT BEHAV. 257, 270-71 (2011); Galas, supra note 
184, at 1074. 
200. See Alison Knopf, NADCP supports MAT but questions lack of 
medication protocols, ALCOHOLISM & DRUG ABUSE WEEKLY (July 21, 
2014), http://www.alcoholismdrugabuseweekly.com/m-article-
detail/nadcp-supports-mat-but-questions-lack-of-medication-
protocols.aspx. 
201. See id. 
202. See Cherkis, supra note 16. 
203. See id.   
204. See generally Matthew Stanbrook, Addiction is a Disease: We Must 
Change Our Attitudes Towards Addicts, 184 CANADIAN MED. ASS. J. 
155, 155 (2012). 
205. See Murphy, supra note 199; Galas, supra note 184, at 1074-75. 
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on the other hand, does not require seeking forgiveness, making 
amends, or developing any kind of spirituality.  NA’s focus on 
morality also makes it particularly attractive to criminal justice 
administrators, including drug court judges, who are trying to reform 
“criminals.” 
NA (through its headquarters) has not officially taken a position 
against MAT.206  However, according to the main website of NA, 
individual NA groups are permitted to decide whether or not to ban 
participants who use MAT from attending meetings.207  Not 
surprisingly, published studies report that some members of NA and 
similar twelve-step groups feel stigmatized if they use MAT.208  For 
example, these members report not telling their sponsors about their 
medical treatment, because sponsors might misunderstand it as 
substituting one chemical addiction for another.209  NA and similar 
groups are also unlikely to educate members about the existence of 
buprenorphine and other forms of MAT.210  Therefore, NA contributes 
to the underuse of buprenorphine: indirectly through the cultural 
norm of abstinence-only treatment, and directly (in some groups) by 
preventing MAT patients from attending meetings.211 
B. Effects of the War on Drugs 
The War on Drugs contributes to the underuse of buprenorphine 
in two ways: by stigmatizing drug-dependent individuals and by 
causing them to hide their illness (rather than seeking treatment) out 
 
206. See NA Groups and Medication, NARCOTICS ANONYMOUS (2007), 
http://www.na.org/admin/include/spaw2/uploads/pdf/servicemat/Dec2
011_NA_Groups_and_Medication.pdf. 
207. See id. 
208. See WILLIAM WHITE, NARCOTICS ANONYMOUS AND THE 
PHARMACOTHERAPEUTIC TREATMENT OF OPIOID ADDICTION IN THE 
UNITED STATES 24, 44-45, 53(2011). 
209. See id. at 26-27. See also Hearing on Heroin and Prescription Drug 
Abuse, supra note 5 (“Medication-assisted treatments remain grossly 
underutilized in many addiction treatment settings, where stigma and 
negative attitudes (based on the misconception that buprenorphine or 
methadone “substitute a new addiction for an old one”) persist among 
clinic staff and administrators.”). 
210. See WHITE, supra note 208, at 22 (“Seen as a whole, NA literature 
defines the use of medically supervised methadone maintenance and 
other pharmacotherapies for opioid addiction as differing little from 
illicit drug use or alcohol use. It asserts that views restricting the 
participation of NA members on medications like methadone and 
buprenorphine are means of asserting NA’s philosophy of complete 
abstinence and maintaining the recovery atmosphere of NA meetings.”). 
211. See id. 
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of fear of punishment for drug possession.  Since the 1970s, the U.S. 
has conducted a “War on Drugs,” so named by President Nixon.212  
The War on Drugs is characterized by criminal prosecution of drug 
possessors and suppliers, with little focus on treatment for drug 
dependence.213  From an economic perspective, it is supply focused 
rather than demand focused. Unfortunately, the effectiveness of the 
War on Drugs seems minimal at best according to most political 
science and criminal justice scholars.214   
Because drugs are illegal, many people believe that drug 
dependence itself is immoral.215  This misconception is bolstered by 
the fact that drug dependence is not a defense to a crime of drug 
possession.216  However, medical authorities, such as the American 
Medical Association, and even NA/AA, have called drug dependence 
a disease, not a moral failing.217  Even if the first episode of drug 
abuse is voluntary, for many individuals repeated drug abuse becomes 
physically and psychologically compulsive.218  As a result, will-power 
is usually insufficient to stop addictive behavior.219  Unfortunately, the 
War on Drugs perpetuates the common misconception that drug 
dependence is a personal choice and a personal failing rather than a 
disease, because the War on Drugs focuses government resources on 
prosecution of drug offenders rather than on treatment of 
dependence.220 
 
212. See generally John Cutcliffe & Belal Saadeh, Grounded in Evidence or a 
Puritanical Legacy: A Critique of Twenty-First Century U.S. Drug 
Policy, 7 MENTAL HEALTH & SUBSTANCE USE 195, 195 (2014). 
213. See id. at 196. 
214. See, e.g., id. at 195. 
215. See generally Stanbrook, supra note 204; Jennifer Murphy, Drug Court 
as Both a Legal and Medical Authority, 32 DEVIANT BEHAV. 257, 258 
(2011). 
216. See United States v. Moore, 486 F.2d 1139, 1147 (D.C. Cir. 1973). 
217. See Galas, supra note 184, at 1074. 
218. See generally Steven Hyman & Robert Malenka, Addiction and the 
brain: The neurobiology of compulsion and its persistence, 2 NATURE 
REVIEWS NEUROSCIENCE 695 (2001). 
219. See generally id. 
220. See Kalynn Amundson et al., Pathologies of the Poor: What do the War 
on Drugs and Welfare Reform Have in Common? 41 J. SOCIOLOGY & 
SOCIAL WELFARE 5, 17 (2014) (A study of rhetoric used in the War on 
Drugs found, “Most references to drug addiction, in both War on Drugs 
and Welfare Reform documents, were largely from a punitive criminal 
justice frame advocating punishment, rather than a medical frame, 
which views addiction as a medical condition requiring treatment, 
although there were some mentions of treatment and rehabilitation.”). 
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The U.S. spends billions of dollars annually on the War on 
Drugs.221  According to the Federal Bureau of Prisons, in December 
2014, 48.7% of individuals in federal prisons were incarcerated for 
drug offenses.222  Incarceration of drug offenders, especially non-violent 
drug offenders, contributes to the U.S. having the highest 
incarceration rate in the world.223  Incarceration for non-violent drug 
crimes has especially devastated many African American families and 
neighborhoods.224  Individuals who are convicted of drug possession, 
including marijuana possession, are ineligible for food stamps, public 
cash assistance, student educational loans, and (in some states) the 
use of a driver’s license.225  Therefore, admission of drug dependence 
to a doctor or a counselor may strike fear in the heart of many people 
who do not understand privacy laws, preventing help-seeking 
behavior.   
In this cultural context riddled with misconceptions about drug 
dependence, the Affordable Care Act has called substance abuse 
treatment one of the ten essential services that must be offered by 
expanded Medicaid programs and by insurance on government-run 
exchanges.226 Former U.S. deputy drug czar, A. Thomas McLellan, has 
said, “There is no illness that will be more favorably affected [by the 
Affordable Care Act] than substance abuse.”227   However, with the 
 
221. See Jeffrey Timberlake et al., How Should We Wage the War on Drugs? 
Determinants of Public Preferences for Drug Control Alternatives, 31 
POL’Y STUD. J. 71, 72-73 (2003). 
222. Offenses, FED. BUREAU OF PRISONS (Dec. 27, 2014), 
http://www.bop.gov/about/statistics/statistics_inmate_offenses.jsp. 
223. See Criminal Justice Fact Sheet, NAACP (2015), 
http://www.naacp.org/pages/criminal-justice-fact-sheet. 
224. See Lisa Moore & Amy Elkavich, Who’s Using and Who’s Doing Time: 
Incarceration, The War on Drugs, and Public Health, 98 AM. J. PUB. 
HEALTH 782, 784 (2008). 
225. See U.S. DEP;T OF HEALTH AND HUMAN SERVS., ARE YOU IN RECOVERY 
FROM ALCOHOL OR DRUG ADDICTION? KNOW YOUR RIGHTS 12-13, 
https://store.samhsa.gov/shin/content/PHD1091/PHD1091.pdf (last 
visited Feb. 9, 2015). 
226. See Substance Abuse and the Affordable Care Act, OFFICE OF NATIONAL 
DRUG CONTROL POLICY, http://www.whitehouse.gov/ondcp/healthcare 
(last visited Feb. 9, 2015) (“The ACA includes substance use disorders 
as one of the ten elements of essential health benefits. This means that 
all health insurance sold on Health Insurance Exchanges or provided by 
Medicaid to certain newly eligible adults starting in 2014 must include 
services for substance use disorders.”). 
227. Anna Gorman, Barriers Remain Despite Health Law’s Push to Expand 
Access to Substance Abuse Treatment, KAISER HEALTH NEWS (Apr. 10, 
2014), http://kaiserhealthnews.org/news/substance-abuse-treatment-
access-health-law/. 
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ongoing background of the War on Drugs, many Americans may feel 
confused about whether or not it is “safe” for them to seek treatment 
for drug dependence.228   
Finally, the War on Drugs has stigmatized individuals suffering 
from substance-abuse by labeling them as criminals.  Individuals with 
stigmatized medical problems are particularly likely to hide their 
medical problems and not seek medical treatment.229  Such was the 
case historically with HIV/AIDS.230  Persons with dependence 
problems do not want their friends, family, and co-workers to think of 
them as criminals or moral failures.231   
C. Undersupply of Doctors with a DATA Waiver 
In 2012, only 46.6% of U.S. counties had at least one physician 
with a DATA waiver.232  Only 2% of all U.S. physicians have a DATA 
waiver, and only 3% of primary care physicians (the largest group of 
physicians in the nation) have obtained a DATA waiver.233  Even 
though any physician with a DATA waiver may prescribe 
buprenorphine, primary care doctors are especially well-positioned to 
help individuals with substance abuse. 
First, a primary care doctor is usually the first doctor with whom 
a person is able to obtain an appointment.  Primary doctors are the 
“gateway” to medical treatment.234  For example, commercial 
insurance often requires a referral from a primary care doctor before a 
patient sees a specialist.  In some towns, a primary care doctor is the 
only type of doctor available, because the population size is too small 
to support specialist physicians.  According to one medical study, 
psychiatrists are the group of physicians most likely to obtain a 
DATA waiver, yet “they are rare or nonexistent in rural America.”235  
 
228. See Richard C. Rapp et al., Treatment Barriers Identified by Substance 
Abusers Assessed at Centralized Intake Unit, 30 J. SUBSTANCE ABUSE 
TREATMENT 227, 228 (2005). 
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(2013). 
231. See id., at 111-12. 
232. See Roger Rosenblatt et al., Geographic and Specialty Distribution of 
U.S. Physicians Trained to Treat Opioid Use Disorder, 13 ANNALS OF 
FAMILY MED. 23, 25 (2015). 
233. See id. 
234. See generally Leiyu Shi, The Impact of Primary Care: A Focused 
Review, 2012 SCIENTIFICA 1 (2012). 
235. Rosenblatt et al., supra note 232, at 25. 
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Second, appointment fees to see a primary care doctor are 
typically lower than those to see a specialist.236  Substance abuse is 
correlated with having a low income, so the cost of seeing a specialist 
may be a significant barrier to individuals seeking treatment.237  
Third, a primary care doctor is frequently the “family doctor” that 
the patient has been seeing for many years.238  Therefore, a primary 
care doctor may have a more extensive understanding of the patient’s 
background, health history, and needs than a specialist would.  
Lastly, an appointment with a primary care doctor provides an extra 
layer of anonymity for patients suffering from drug dependence, 
because primary care doctors treat many different types of less 
stigmatized conditions.   For example, seeing a psychiatrist is more 
stigmatized than seeing a primary care doctor.239   
The reason for low DATA waiver rates among primary care 
doctors is not fully understood, but published studies point to a few 
possible explanations based on surveys and interviews with primary 
care doctors.240  First, many primary care doctors feel that they know 
too little about drug dependence to provide adequate treatment or 
believe that they are underqualified.241  However, DATA waiver 
requirements include an eight hour training course, which should 
somewhat ameliorate this concern.242  Furthermore, primary care 
provision of buprenorphine treatment is just as effective as 
buprenorphine treatment in more specialized settings.243  According to 
an article published in the Annals of Family Medicine, 54% of 
patients were sober at six months of buprenorphine treatment from a 
primary care doctor.244 Second, some doctors fear stigma within the 
 
236. See Shi, supra note 234, at 10-11. 
237. See Chaloupka et al., supra note 120, at 3. 
238. See Shi, supra note 235, at 2 (stating that primary care “refers to family 
medicine services… and is person-oriented, longitudinal care”). 
239. See generally Reuven Bar-Leyav, The Stigma of Seeing a Psychiatrist, 
30 AM. J. PSYCHOTHERAPY 473, 473-74 (1976). 
240. See Eliza Hutchinson et al., Barriers to Primary Care Doctors 
Prescribing Buprenorphine, 12 ANNALS OF FAM. MED. 128 (2014). 
241. Id. at 131; Saxon & McCarty, supra note 16, at 123; Norman S. Miller 
et al., Why physicians are unprepared to treat patients who have 
alcohol- and drug-related Disorders, 76 ACAD. MED. 410, 410 (2001). 
242. See U.S. DEP’T OF HEALTH & HUMAN SERVS., BUPRENORPHINE TRAINING 
FOR PHYSICIANS, http://www.samhsa.gov/medication-assisted-
treatment/training-resources/buprenorphine-physician-training (2016). 
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FAMILY MED. 146, 149 (2007). 
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medical community for treating opioid dependent individuals, 
including disapproval from staff, medical partners, or institutional 
administration.245   Such stigma is an extension of the larger cultural 
phenomenon of labeling drug-dependent individuals as immoral 
persons rather than ill individuals.  Third, some primary care doctors 
simply believe that they have very few patients suffering from drug 
dependence.246  However, this belief is probably naïve given the rising 
trend of opioid dependence and opioid overdoses.247  Patients with 
substance abuse problems may feel uncomfortable discussing their 
problem with their doctor, especially if they have not received any 
signal from the doctor suggesting that treatment is available or that 
such a conversation would be confidential.  Fourth, doctors have 
described the DATA waiver process as being too time-consuming or 
bureaucratic.248  However, other than an eight hour training course, 
there are few ongoing, time-consuming requirements for a doctor to 
comply with DATA after obtaining a DATA waiver.  Finally, some 
surveyed primary care doctors have expressed apathy towards 
treating drug dependence.249  This attitude is probably a cover for 
personal bias or other reasons that that the doctor would rather not 
express.  After all, it is difficult to imagine a physician being 
genuinely disinterested in treating diabetes, asthma, or another 
serious chronic condition for which effective medication is available.   
D. Patient Limits under DATA 
The American Medical Association and the American Society for 
Addiction Medicine have repeatedly criticized the patient limits in 
DATA250 as being arbitrary and causing unnecessary waitlists for 
patients.251  Such patient limits do not exist for other Schedule III 
narcotics.252  They do not even exist for oxycodone, a Schedule II 
 
245. See generally Hutchinson, supra note 240. 
246. See Barry et al., supra note 84, at 222. 
247. See Chen et al., supra note 1, at 2. 
248. Hutchinson, supra note 240, at 131. 
249. See Barry et al., supra note 84, at 221.  
250. See 21 U.S.C..§ 823(g). 
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effective, FDA-approved pharmacotherapies to treat opioid addiction. 
Unfortunately, they all come with arbitrary treatment limits that have 
resoundingly negative effects on treatment access and outcomes.”). See 
151 CONG. REC. H6679-H6681 (daily ed. July 27, 2005) (Statements of 
Reps. Deal and Souder).  
252. See Melissa Ferrara, Comment: The Disparate Treatment of Addiction-
Assistance Medications and Opiate Pain Medications Under the Law: 
Permitting the Proliferation of Opiates and Limiting Access to 
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narcotic and the substance to which many opioid dependent 
individuals are addicted.253  In cities with buprenorphine-prescribing 
physicians, patient limits may cause long waitlists, sometimes with 
hundreds of patients.254  Buprenorphine is an effective maintenance 
treatment that can be used indefinitely, so once patients begin 
buprenorphine treatment, they are likely to have regularly scheduled 
appointments for a long time.  As a result, persons on waitlists may 
need to wait many months until someone else stops treatment.255   
E. Bias from Mental Health Therapists 
The field of drug dependence treatment is deeply divided between 
individuals who support the use of MAT and individuals who oppose 
its use, especially within the field of counseling.256  A large minority of 
mental health therapists have either never heard of buprenorphine or 
oppose the use of buprenorphine.257  
Therapists who oppose the use of buprenorphine are unlikely to 
educate patients about buprenorphine’s availability and benefits.258  A 
therapist is most likely to oppose the use of buprenorphine if the 
therapist is philosophically aligned with abstinence-only, twelve-step 
groups, such as NA.259  A therapist is more likely to accept the use of 
buprenorphine if the therapist works in an institution that already 
prescribes buprenorphine.260   
Mental health therapists have an important role to play in 
educating patients about effective drug dependence treatment.  Even 
though mental health therapists cannot prescribe buprenorphine, they 
can refer patients to psychiatrists or other doctors for the medication.  
Counselors are already comfortable with referring patients for other 
medication, such as anti-depressants.  For example, a survey by the 
American Psychological Association found that 98% of psychologists 
 
Treatment, 42 SETON HALL L. REV. 741 (2012); Saxon & McCarty, supra 
note 16, at 124 (“There are few, if any, other approved medications that 
can be prescribed only by physicians who meet certain standards.”). 
253. See id. at 750-52. 
254. See Cherkis, supra note 16. 
255. See id. 
256. See Knudsen et al., supra note 185.   
257. See id. 
258. See id. 
259. See id. at 103. 
260. See id. 
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have referred patients to physicians for some kind of mental health 
medication.261   
Some mental health counselors may assume that buprenorphine 
and counseling are diametrically opposed.  However, the most 
effective form of treatment for drug dependence is medication 
combined with mental health therapy, especially cognitive behavioral 
therapy. 262  Furthermore, DATA recognizes the concurrent roles of 
medication and counseling in dependence treatment, because DATA 
requires a buprenorphine-prescribing physician to be able to refer a 
patient to ancillary mental health services.263 Likewise, methadone 
clinics are required to provide counseling and rehabilitative services.264  
F. Cost and Medicaid Limits 
The cost of buprenorphine treatment may serve as a disincentive 
for some individuals.  Buprenorphine treatment has two cost 
components: physician visits and the prescription itself.  Major 
commercial health insurance covers both treatment components. 265  
However, many patients suffering from opioid dependence are low-
income individuals,266 and, therefore, are less likely to have 
commercial health insurance than higher-income individuals. Also, 
many dependent individuals are unemployed, because a circular, 
causal relationship exists between unemployment and drug 
dependence.267  Unemployed individuals are unlikely to have 
commercial health insurance, because such insurance is usually 
obtained through one’s employer.  However, the ACA may make 
commercial insurance more accessible. 
 
261. See Laurie Meyers, American Psychological Association, Psychologists 
and Psychotropic Medication, 37 MONITOR 46, 46 (2006), 
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Services, supra note 20, at 2, http://www.healthvermont.gov/ 
adap/documents/HUBSPOKEBriefingDocV122112.pdf (“Medication 
assisted therapy (MAT), such as methadone and buprenorphine in 
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effective treatment for opiate addiction.”).  See also What are the 
treatments for heroin addiction?, supra note 20. 
263. See CHILDREN’S HEALTH ACT OF 2000, Pub. L. No. 106-310,  
§ 3502 (codified at 21 U.S.C. § 823(g) (2006 & West Supp. 2009)). 
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TREATMENT 94 (Richard A. Rettig & Adam Yarmolinsky eds.1995). 
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266. See Chaloupka, supra note 120, at 10. 
267. See Dieter Henkel, Unemployment and Substance Use: A Review of the 
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Low-income or unemployed individuals may or may not be 
eligible for Medicaid, depending on the income threshold in their state 
for Medicaid eligibility and other state-based eligibility characteristics. 
States that did not choose to expand Medicaid under the ACA may 
bar young, single males from obtaining Medicaid coverage. Even if the 
patient is covered by Medicaid, some states’ Medicaid programs have 
limits on the length of time the patient can remain on buprenorphine 
treatment.268  These “lifetime limits” may be as short as 1 year.269  
Medical authorities are strongly opposed to such limits, because long-
term buprenorphine treatment is more effective than short-term 
buprenorphine treatment.270   
Buprenorphine treatment requires regular physician visits.  
Because buprenorphine is a Schedule III narcotic, the federal 
government allows automatic refills for up to 6 months or 5 refills.271  
However, in practice, many physicians do not prescribe automatic 
refills, and instead require that the patient return for an appointment 
monthly.272 Specialists are more likely than primary care doctors to 
have a DATA waiver, so chances are that a patient undergoing 
buprenorphine treatment will need to regularly pay for an 
appointment with a specialist.273  Unfortunately, appointment costs 
(with or without health insurance) tend to be more expensive for 
specialists than for primary care doctors.274 This cost could act as a 
disincentive to begin or continue buprenorphine treatment. 
The cost of the medication, as discussed in Part II, varies widely.  
The monthly cost depends on whether or not the patient has health 
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270. See id. 
271. See 21 C.F.R. § 1306.22. 
272. See 15 Ways to Save Money on Buprenorphine Treatment, supra note 
83 (“As the patient stabilizes, s/he can request to have less frequent 
office visits. Although physicians commonly require patients to come in 
for appointments every month to monitor the patient’s 
progress, schedule III medications can be refilled up to 5 times in a 6 
month period.  Visit frequency is ultimately determined by the 
physician, but it doesn’t hurt to ask, particularly for those stable in 
long-term addiction remission and those who get therapy or counseling 
from other sources. Some states however, overrule the physician’s 
judgment and have set minimum periods between office visits.”). 
273. See Rosenblatt et al., supra note 232, at 24. 
274. See generally Shi, supra note 234, at 10-12. 
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insurance coverage or Medicaid, purchases generic Suboxone, or pays 
with a discount card from a pharmaceutical company.275  
G. Concerns of Diversion 
Some major newspapers have published articles regarding 
diversion and abuse of buprenorphine, possibly discouraging some 
physicians from prescribing it.276   Buprenorphine can be overdosed or 
abused.  However, buprenorphine overdoses are rare relative to 
heroin, oxycodone, or methadone overdoses.277  There are two reasons 
for this.  First, the partial mu-antagonist nature of buprenorphine 
prevents the patient from experiencing euphoria from taking any 
additional opioid (including extra buprenorphine).278  Second, 
buprenorphine is far less potent than heroin, oxycodone, methadone, 
and other common opioids.279   
Buprenorphine is sometimes diverted to the black market (sold on 
the street).  However, some recent studies have found that individuals 
who purchase buprenorphine on the black market are more likely to 
do so in order to help themselves become sober (i.e. as treatment) 
rather than to get “high.”280  These individuals may find it easier to 
purchase buprenorphine illicitly than to obtain an appointment with a 
buprenorphine-prescribing doctor.281  The bizarre fact that a black 
market has developed for treatment medication points to the high 
demand for treatment relative to the supply of providers.282   
V. The Treat Act 
In 2013, Senator Markey introduced The Recovery Enhancement 
for Addiction Treatment Act (TREAT Act), Bill S. 2645 (2013), 
which has the potential to significantly expand access to 
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buprenorphine treatment.283  Bill S. 2645 (2013) version never made it 
past committee. However, the TREAT Act has been reintroduced in 
the Senate in 2015 as Bill S. 1455 (2015), with a corresponding 
version introduced in the House of Representatives, Bill H.R. 2536 
(2015).284  Part A of this section outlines the contours and objectives 
of the proposed TREAT Act.  Part B discusses the benefits of the 
proposed Act. Part C offers some suggestions for strengthening the 
TREAT Act, so that it can better address reasons for buprenorphine’s 
underuse. 
A. Proposed Provisions of the TREAT Act: 
The purpose of the TREAT Act is to increase access to 
buprenorphine treatment for individuals dependent on opioids.285  
Consequentially, the TREAT Act is intended to reduce deaths from 
opioid overdose, criminal activity, and HIV-transmission associated 
with opioid injections.286  If passed, the TREAT Act would 
substantively amend the CSA in two ways.  First, it would allow 
qualified nurse practitioners and physician assistants to provide 
buprenorphine treatment.287  Second, it would allow practitioners to 
treat far more patients by increasing the patient limit threshold.288     
1. Expansion of the Definition of Practitioner 
The TREAT Act would allow any “qualifying practitioner” to 
prescribe buprenorphine.289  Under DATA, only a licensed physician 
may become a qualified practitioner, but the TREAT Act would 
allow certain licensed physician assistants and nurse practitioners to 
 
283. See also Recovery Enhancement for Addiction Treatment Act, S.2645, 
113th Congress (2014). 
284. See Major Actions-  
Recovery Enhancement for Addiction Treatment Act, S.1445, 
CONGRESS.GOV (2015),   https://www.congress.gov/bill/114th-congress/ 
senate-bill/1455/all-actions?q={%22search%22%3A[%22RECOVERY+ 
ENHANCEMENT+FOR+ADDICTION+TREATMENT+ACT+S2645
%22]}&resultIndex=2 (last visited October 20, 2015) (“Read twice and 
referred to the Committee on Health, Education, Labor, and 
Pensions.”); Major Actions - Recovery Enhancement for Addiction  
Treatment Act, H.R. 2536, CONGRESS.GOV (2015),  https://www. 
congress.gov/bill/114th-congress/house-bill/2536/all-Actions? 
q={%22search%22%3A[%22\%22hr2536\%22%22]}&resultIndex=1.  
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113th Cong. (2015). 
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also become qualified practitioners.290  The bill refers to them as 
“qualified physician assistants and nurse practitioners.”291  In order to 
become qualified, a physician assistant or nurse practitioner must 
meet all of the following criteria: 
(i) be licensed under state law to prescribe Schedule III, IV, or 
V medications for pain; and 
(ii) have completed at least 24 hours of training in addiction 
medicine (or have experience the Secretary deems to be 
equivalent); and 
(iii) practice under a physician who both 
a. holds an active waiver to prescribe buprenorphine; and 
b. fulfills one of the following criteria: 
i. is board certified as an addiction medicine specialist by 
a medical association listed in the statute, or  
ii. practices in a qualified health care setting.292  
The supervising physician requirement is quite restrictive, but 
easy to overlook if one quickly reads the statute.293  Not every 
physician with a DATA waiver can supervise physician assistants or 
nurse practitioners.294  To become a supervising physician, the 
physician must be “board certified” as an addiction specialist by one 
of the listed medical authorities (such as the American Society of 
Addiction Medicine), or must practice in a qualified health setting.295  
There is a list of qualified practice settings in Section 4(2) of the Act, 
including the following settings: an Accountable Care Organization, a 
Department of Veterans Affairs clinic, and prison clinics.296   
In other words, a physician who merely completed the eight hour 
certification course may himself or herself prescribe buprenorphine, 
but he or she may not act as “supervisor” for a nurse practitioner or 
physician assistant for purposes their qualification under the Act.297   
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Presumably, the sponsors of the TREAT Act are concerned with the 
quality of supervision that a physician who only took a brief addiction 
treatment certification course could provide to nurse practitioners or 
physician assistants.298   
2. New Patient Limits 
Under DATA, a physician may treat up to 30 patients during her 
first year of having a DATA waiver, and 100 patients thereafter.299  
The TREAT Act, on the other hand, would allow a qualifying 
practitioner (whether a physician, nurse practitioner, or physician 
assistant) to treat up to one hundred patients during the first year.300 
After the first year, the TREAT Act would allow the qualifying 
practitioner to submit a notification to the Secretary of Health 
signifying the need and intent to treat an unlimited number of 
patients.301  The Secretary would then permit the qualifying 
practitioner to treat an unlimited number of patients, so long as the 
practitioner meets all of the criteria of one of the following paths.302 
a. Path 1: Practitioners Qualifying via Board Certification  
The first path only applies to practitioners who became qualified 
to treat 100 patients by virtue of having a Board Certification as an 
addiction medicine specialist from a medical authority listed in the 
statute (such as the American Society for Addiction Medicine).303 The 
practitioner only needs to participate in the Prescription Drug 
Monitoring Program of the State in which the practitioner is 
licensed.304 
b. Path 2: Practitioners Qualifying via Training Course, Investigating 
a Clinical Trial, or Other Methods  
An alternate path is for practitioners who are already qualified to 
treat 100 patients by virtue of having either taken an eight hour 
training course, acted as an investigator in a clinical trial of 
buprenorphine (or similar medication), or otherwise convinced the 
U.S. Secretary of Health and Human Services or state medical board 
of their ability to treat opioid-addicted patients.305 
 
298. See id. 
299. See id., at § 3. 
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In order to satisfy this path, the practitioner must meet all of the 
following criteria: 
(a) Participate in the Prescription Drug Monitoring Program of 
the State in which the practitioner is licensed; and 
(b) Practice in a qualified setting (defined in 4 (II)(cc)(BB)); 
and 
(c) Complete at least 24 hours of addiction medicine training 
(including the 8 hours already taken).306   
B. Discussion of the TREAT Act 
1. Why it’s Good 
The TREAT Act is supported by a long list of American medical 
authorities, including the following: the American Medical 
Association, the American Society of Addiction Medicine, the 
American Association of Nurse Practitioners, the Association of 
American Medical Colleges, Trust for America’s Health, the National 
Association of State Alcohol and Drug Abuse Directors, and the 
National Association of County and City Health Officials.307  However, 
the general public and popular media hardly seem to have noticed the 
proposed bill.308    
The TREAT Act is good for physicians, because it would allow 
them to treat more patients with buprenorphine, thus effectively 
increasing the benefits of obtaining a DATA waiver relative to the 
costs of obtaining a waiver.  The TREAT Act is also good for opioid 
dependent individuals who are seeking treatment, because they will 
have an easier time obtaining an appointment for buprenorphine 
treatment if more practitioners are available (in the form of nurse 
practitioners and physician assistants) and if patient limits are 
loosened.  
In July of 2014, the president of the American Society of 
Addiction Medicine, Stuart Gitlow, sent a letter to Senator Markey 
commending the proposed TREAT Act for its potential to improve 
access to treatment by increasing the number of buprenorphine-
treatment practitioners.309  The letter states that approximately 5000 
 
306. See id. 
307. See Senator Edward Markey, The Recovery Enhancement for Addiction 
Treatment Act (TREAT Act) (2015), http://www.markey.senate.gov/ 
imo/media/doc/2015-05-27-OnePager-TREAT-Act-.pdf. 
308. A Google search by the author on February 9, 2015, did not result in 
any mainstream newspaper headlines regarding the TREAT Act. 
309. See, e.g., ASAM Letter, supra note 43. 
Health Matrix·Volume 26·Issue 1·2016 
America Needs the TREAT Act:  
Expanding Access to Effective Medication for Treating Addiction 
353 
board certified addiction physicians are currently trained to treat 
opioid dependence, but, 
There are tens of thousands more primary care physicians and 
advanced practice clinicians like nurse practitioners and 
physician assistants who, with significant specialized training 
and access to the aforementioned specialists, can also advance 
the use of buprenorphine and thereby help fill the treatment 
gap.310 
The letter also commends the TREAT Act for decreasing patient 
limits and eliminating them altogether for certain qualified 
practitioners.311  According to Gitlow’s letter, the current restrictions 
on this “life-saving medication” are “arbitrary.”312  
The expansion of the definition of “qualified practitioners” to 
include nurse practitioners and physician assistants is a critical step in 
increasing access to buprenorphine.  Today many cities do not have a 
single physician with a DATA waiver,313 and many physicians with 
DATA waivers have very long waitlists.  The Huffington Post 
recently stated that one Ohio county clinic has a waitlist of over 500 
patients.314   
Likewise, the change in patient limits from 30 to 100 in the first 
year and from 100 to an unlimited number in the second year has the 
potential to dramatically shorten waitlists for patients.315  In theory, 
Americans should be deeply concerned about the waitlists that many 
opioid-dependent individuals must face when seeking treatment.  
After all, the popular media criticizes waitlists in other countries, 
even when those waitlists are for elective procedures.316  
Buprenorphine, on the other hand, is life-saving, essential medicine.317  
Furthermore, buprenorphine treatment has been found to reduce 
 
310. Id. 
311. See id. 
312. Id. 
313. See Rosenblatt, supra note 233, at 25. 
314. See Cherkis, supra note 16. 
315. See Recovery Enhancement for Addiction Treatment Act S.2645, 113th 
Congress (2014). 
316. See, e.g., David Frum, How Long Do Canadians Wait for Healthcare?, 
DAILY BEAST (Jun. 20, 2012), http://www.thedailybeast.com/ 
articles/2012/06/20/canadian-healthcare.html. See also Queue-Jumping 
a Fact, Alberta Medical Inquiry Finds, CBC NEWS (Aug. 21, 2013), 
http://www.cbc.ca/news/canada/calgary/queue-jumping-a-fact-alberta-
medical-inquiry-finds-1.1393856. 
317. See, e.g., WHO Model List of Essential Medicines, supra note 40.  
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drug-related crime,318 health care costs (particularly for emergency 
room visits), and unemployment.319   
The point at which an opioid-dependent individual recognizes 
that he or she has a problem and seeks help is an absolutely critical 
window that can quickly disappear.320  It is a tragedy for a person 
with a debilitating addiction to recognize that he or she needs help 
but is unable to obtain it due to government-mandated patient limits.  
The cravings for opioids and the withdrawal symptoms a person 
experiences when they try to become sober may quickly overcome the 
desire to seek treatment if an appointment with a physician cannot be 
obtained.   
The TREAT Act would not only help save the lives of addicted 
individuals, it would also be a tremendous relief to their families.  
Few circumstances are more tragic than seeing a spouse, parent, child, 
or sibling suffer from a deadly chronic disease, especially one that 
frequently leads to lack of employment and incarceration.  Families 
too frequently bear the financial and emotional burden of having to 
support individuals struggling with drug dependence.  
2. How to Make the TREAT Act Great 
With some hesitation, this article’s author would recommend four 
additions to the proposed TREAT Act.  The hesitation stems from 
the fact that the legislative process of proposing amendments could 
cause the passage of the Act to become severely delayed or even 
completely derailed in one of many potential legislative “vetogates,”321  
The bill is co-sponsored by Senators Feinstein (D), Rockefeller (D), 
Brown (D), Hirono (D), and Durbin (D).322  Unlike the bipartisan 
sponsors of DATA, the co-sponsors of the TREAT Act are all 
 
318. See Erol Digiusto et al., Effects of Pharmacotherapies for Opioid 
Dependence on Participants’ Criminal Behavior and Expenditure on 
Illicit Drugs: An Australian National Evaluation (NEOPD), 39 AUSTL. 
& N.Z. J. CRIMINOLOGY 171, 172, 183-85 (2006). 
319. See generally Amine Khemiri et al., Analysis of buprenorphine/nalexone 
dosing impact on treatment duration, resource use, and costs in the 
treatment of opioid dependent adults: a retrospective study of U.S. 
public and private health care claims, 126 POSTGRAD. MED. J. 113 
(2014). 
320. See Detoxification and Substance Abuse Treatment Training Manual, 
SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN. 13 (2008), 
http://store.samhsa.gov/shin/content/SMA09-4331/SMA09-4331.pdf; 
Stöver, supra note 23, at 45. 
321. See William Eskridge, Vetogates and American Public Law, J. LAW 
ECON. ORG. *3 (2012). 
322. See Recovery Enhancement for Addiction Treatment Act, S.2645, 113th 
Congress (2014). 
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Democrats. 323  At the time of this article’s writing, the bill is in the 
Senate Committee on Health, Education, Labor, and Pensions,324 
which is chaired by Senator Alexander (R).  The committee has a 
slight Republican majority (12 Republicans versus 10 Democrats), but 
it includes Senator Hatch (R) who proposed the original version of 
DATA.325  In this current era of extremely polarized politics, any 
amendment could derail the bill.  Sometimes it is better to simply 
allow a “good” bill to become law than to propose changes to make it 
“great.”   
With that caveat in mind, this author would propose the 
following four additional provisions to the TREAT Act: a) 
significantly increased federal funding for grants used to educate 
health practitioners and the public about evidence-based addiction 
treatment; b) financial incentives for Medicaid to cover buprenorphine 
without lifetime limits; c) federal block grants to states that agree to 
cover the cost of the eight hour training course necessary for many 
health practitioners to obtain a DATA waiver; and d) federal grants 
for studying both the reasons for underutilization of addiction 
medicine and potential government policies to increase its utilization.  
a. Federal Funding for Educational Grants 
First, the TREAT Act should significantly increase funds in the 
form of grants to cities, universities, and non-profit organizations to 
educate citizens, physicians, nurse practitioners, physician assistants, 
hospitals, in-patient and out-patient rehabilitation centers, and 
mental health therapists about the proven benefits of evidence-based 
treatment for opioid-dependence, including buprenorphine.326  Many 
primary care doctors never seek a DATA waiver simply because they 
do not know about buprenorphine or feel that they lack the 
knowledge to provide treatment.327  This is not surprising, given that 
most medical students receive little education in addiction medicine.328  
 
323. Id. 
324. Major Actions: S. 2645 – 113th Congress (2013-2014), CONGRESS.GOV, 
https://www.congress.gov/bill/113th-congress/senate-bill/2645/ 
actions?q=%7B%22search%22%3A%5B%22RECOVERY+ENHANCEM
ENT+FOR+ADDICTION+TREATMENT+ACT%22%5D%7D (last 
visited Feb. 10, 2015). 
325. U.S. SENATE COMMITTEE ON HEALTH, EDUCATION, LABOR, AND 
PENSIONS, http://www.help.senate.gov/ (last visited Feb. 10, 2015). 
326. See, e.g., Matusow, supra note 12, at 479 (arguing that there is a 
“critical need for a strong educational initiative to disseminate evidence 
about MAT efficacy in treating opioid dependence.”). 
327. See Barry, supra note 84. 
328. See Cherkis, supra note 16.  See also Ellen Weber, Symposium: Failure 
Of Physicians To Prescribe Pharmacotherapies for Addiction: 
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However, studies show that buprenorphine works well for opioid-
dependent individuals who see primary care physicians329 (most of 
whom only take the 8 hour course required by DATA).330  Therefore, 
many primary care doctors’ fear of being underqualified is largely 
unfounded.331   
Additionally, a large minority of mental health counselors do not 
know about buprenorphine or oppose the use of buprenorphine 
treatment.332  According to one survey, 41% of mental health 
counselors do not consider buprenorphine to be an acceptable 
treatment, and 54% do not consider buprenorphine to be an effective 
treatment.333 An educational initiative with accurate medical data 
about evidence-based treatment may help many of these counselors 
refer their patients to a physician for buprenorphine treatment.  
Finally, Americans in general should be educated about treatment 
options rather than only being warned about the dangers of drugs.  
The U.S. government has previously created mass media campaigns to 
inform the public of the dangers of smoking and drugs.334  These same 
types of campaigns could incorporate information about effective 
treatment for drug dependence, including buprenorphine.  
Furthermore, by openly talking about medications like buprenorphine, 
a mass educational campaign could help eliminate some of the stigma 
of MAT. 
This suggested amendment to the TREAT Act might not be cost 
neutral.  The Congressional Budget Office will probably find it 
difficult to quantify the benefits of educational grants relative to their 
cost, especially because information diffusion takes time.  However, 
increased public knowledge about buprenorphine will almost certainly 
lead to increased use of buprenorphine.  Increased use of 
buprenorphine will lead to fewer medical, law enforcement, and 
unemployment expenditures by federal and state governments,335 
potentially offsetting costs of increasing educational grants.    
Regulatory Restrictions and Physician Resistance, 13 J. Health Care L. 
& Pol’y 49, 69 (2010). 
329. See Mintzer et al., supra note 240, at 150. 
330. Primary care doctors are unlikely to be Board Certified as Addiction 
Specialists, so most primary care physicians with a DATA waiver 
probably took a certification course, as permitted under DATA. 
331. See Mintzer et al., supra note 243. 
332. See Knudsen et al., supra note 185, at 98.   
333. See Rieckmann et al., supra 185 at 377. 
334. See, e.g., National Youth Anti-Drug Media Campaign, THE WHITE 
HOUSE, http://www.whitehouse.gov/ondcp/anti-drug-media-campaign 
(last visited Feb. 9, 2015). 
335. See infra Part II.C. 
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b. Financial Incentives for Medicaid Coverage of Addiction Medicine 
Second, the TREAT Act should encourage Medicaid programs to 
cover buprenorphine indefinitely for Medicaid eligible individuals who 
have a formal medical diagnosis of opioid dependence.  For example, 
the federal government could agree to bear part of the cost of 
Medicaid beneficiaries’ generic buprenorphine prescriptions, while 
prohibiting the state from placing lifetime limits on buprenorphine 
maintenance treatment.   
According to the National Institute on Drug Abuse (NIDA), 
approximately 12% of Medicaid beneficiaries over the age of eighteen 
have a substance use disorder.336  When Medicaid beneficiaries with 
substance use problems receive MAT, including buprenorphine, 
Medicaid spends 33% less on their health care costs over the first 
three years, and costs continue to decline thereafter.337  Medicaid is a 
block-grant program between the federal government and state 
governments, so costs savings would be shared between the federal 
government and state governments.  Medicaid accounts for the single 
largest expenditure of states’ revenues, so increasing access to MAT 
could significantly decrease total state Medicaid costs, pleasing both 
cultural liberals and fiscal conservatives. 
According to SAMHSA, eleven states’ Medicaid programs set 
lifetime limits on buprenorphine treatment.338  Medicaid programs 
rarely set lifetime limits on medications for other chronic diseases, 
suggesting institutional bias against drug-dependent individuals.339  In 
the case of buprenorphine, lifetime limits negatively affect patient 
safety.340  According to a study published in Health Affairs, “mortality 
rates were… more than twice as high among those receiving no 
treatment, compared to those receiving buprenorphine [through 
Medicaid].”341  Medical studies show that drug abuse relapse is most 
 
336. See Informational Bulletin, supra note 39, at, 1. 
337. See id. 
338. SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., MEDICAID 
COVERAGE AND FINANCING OF MEDICATIONS TO TREAT ALCOHOL AND 
OPIOID USE DISORDERS 2 (2014), http://store.samhsa.gov/shin/ 
content//SMA14-4854/SMA14-4854.pdf. 
339. See id. 
340. See Clark et al., supra note 80, at 1431 (“Although further studies 
measuring the impact of policies that restrict access to buprenorphine 
are needed, this analysis suggests that significant reductions in its use 
could have the unintended effect of increasing costs. Also, if it reduces 
overall use of opioid substitution therapy, a policy restricting 
buprenorphine use might also contribute to higher mortality among 
Medicaid beneficiaries with opioid addiction.”). 
341. Id. at 1425. 
Health Matrix·Volume 26·Issue 1·2016 
America Needs the TREAT Act:  
Expanding Access to Effective Medication for Treating Addiction 
358 
effectively prevented by long-term buprenorphine maintenance 
treatment, not short-term treatment.342  For example, a randomized 
study found that 90% of patients relapse if buprenorphine treatment 
stops after 12 weeks.343  Therefore, individuals who lose Medicaid 
coverage for buprenorphine treatment have a high risk of relapse.344   
Not only is relapse harmful to the individual, it is bad for the 
state budget.  When individuals relapse, they are more likely to need 
expensive emergency room treatment, in-patient rehabilitation, 
and/or hospital treatment due to opioid overdose. 345  According to 
the CDC, every day approximately 7,000 individuals seek emergency 
room treatment for substance abuse-related medical emergencies.346  
Additionally, individuals who relapse are more likely to become 
unemployed than those who do not relapse,347 causing a loss in 
economic productivity.  Finally, individuals who relapse are more 
likely to commit drug-related crimes,348 draining state law enforcement 
resources. 
c. Grants for Physician Certification Courses 
Third, the TREAT Act should authorize the federal government 
to provide block grants to states that agree to at least partially cover 
the cost of the eight-hour certification course necessary for most 
health practitioners to obtain a DATA waiver.349  The federal 
government would bear the remaining cost.  As a result, more 
 
342. See Roger D. Weiss et al., Adjunctive counseling during brief and 
extended buprenorphine-naloxone treatment for prescription opioid 
dependence: A 2-phase randomized controlled trial, 68 ARCH. GEN. 
PSYCHIATRY 1238, 1238 (2011) (explaining that relapse is prevented 
while patients are on buprenorphine, but significantly increases if 
patients taper off buprenorphine). 
343. See id at 1244. 
344. See id. at 1238. 
345. See CDC, PRESCRIPTION DRUG OVERDOSE IN THE UNITED STATES: FACT 
SHEET, http://www.mayorsinnovation.org/images/uploads/pdf/1_-
_Prescription_Drug_Overdose_in_the_United_States.pdf (last visited 
Feb. 9, 2015) (“Every day in the United States, 114 people die as a 
result of drug overdose, and another 6,748 are treated in emergency 
departments (ED) for the misuse or abuse of drugs.”). 
346. See id. 
347. Regarding the relationship between addiction and unemployment, see 
generally Henkel, supra note 267. 
348. Cf. Redonna Chandler et al., Treating Drug Abuse and Addiction in the 
Criminal Justice System: Improving Public Health and Safety, 301  
JAMA 183 (2009). 
349. See Recovery Enhancement for Addiction Treatment Act, S.2645, 113th 
Congress (2014). 
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physicians, nurse practitioners, and physician assistants would be 
more likely to seek a DATA waiver.  A primary care doctor would 
need to take such a course in order to obtain a DATA waiver, as he 
or she is unlikely to already be board certified as an addiction 
specialist.350  As discussed in Part IV, infra, primary care doctors are 
an ideal gateway to addiction treatment, because they have lower fees 
than specialists and are typically the sole physicians in rural areas. 
The block grants could be authorized as a pilot program requiring 
review after one year.  That way, the federal and state governments 
could assess how effective such a program was at inducing primary 
care physicians to obtain a DATA waiver.  Funding of one physician’s 
certification course would allow that physician to treat 100 patients in 
the first year under the TREAT Act.351 Many of the patients are 
likely to be Medicaid beneficiaries.352  As discussed previously, 
Medicaid costs decline for beneficiaries with substance abuse problems 
once these beneficiaries receive MAT.353 Because Medicaid is a block 
grant program between the federal government and state 
governments, both would benefit from savings in Medicaid costs. 
d. Grants to Study Addiction Medicine Underuse 
Finally, the TREAT Act should increase federal funding for 
grants to research reasons for the underutilization of MAT and 
methods to incentivize its use.  Existing but insufficient funding is 
available through the National Institute of Drug Abuse.  Scholars 
should examine the practices, attitudes, norms, and beliefs of decision-
makers in the criminal justice system, health practitioners, and the 
general public.  Most importantly, more legal, criminal justice, and 
health policy researchers should analyze potential government policies 
for expanding the use of MAT.   
This amendment to the TREAT Act would not be cost neutral.  
It will be difficult for the Congressional Budget Office to quantify and 
predict the benefits of grants to study underuse of MAT.  However, 
the information gathered would allow policy makers to tailor 
treatment incentives to targeted populations.  For example, currently 
few state prisons and only half of drug courts offer buprenorphine 
treatment, largely due to stigma against MAT.354  Federal policy 
makers should learn the reasons for abstinence-only treatment 
preferences within states’ criminal justice systems.  Then, they could 
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351. See id., at §3-4. 
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354. See Nunn, supra note 31, at 85-86. 
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specifically address those concerns when creating federal incentives to 
expand MAT.  In the long-run, increased use of MAT in the criminal 
justice system, whether state or federal, will lead to lower recidivism, 
incarceration rates, and costs.355   
VI. Conclusion 
Medication combined with mental health counseling has been 
considered the standard of care for treating opioid dependence for 
decades. 356  Unfortunately, the public, many doctors, and a large 
minority of mental health therapists do not seem to have noticed.  
There are three FDA-approved medications for treating opioid 
dependence: methadone, buprenorphine, and extended release 
naltrexone.357  This article focuses on buprenorphine, because it is the 
most cost-effective and widely used medication assisted treatment.358  
Buprenorphine is a life-saving medication that has been proven to 
decrease relapse, criminal activity, unemployment, and mortality.359  
It is considered an essential medicine by the World Health 
Organization.360   
Buprenorphine treats opioid dependence by partially activating 
and partially blocking the opioid receptor in the brain, thus reducing 
cravings, preventing withdrawals, and preventing euphoria from 
opioids.361  Even though reports of diversion and abuse of 
buprenorphine exist, studies have found that when buprenorphine is 
purchased on the street, it is usually used to get sober, not to get 
“high.”362   
 
355. See id. at 87. 
356. See generally MEDICATION-ASSISTED TREATMENT FOR OPIOID 
ADDICTION, supra note 27, at 5. 
357. See id., at 26.   
358. For a comparison of cost-effectiveness of buprenorphine, Vivitrol, and 
methadone, see Kaskutas, supra note 17. 
359. See Nicholas Zaller et al., Initiation of Buprenorphine during 
Incarceration and Retention in Treatment Upon Release, 45 J. 
SUBSTANCE ABUSE TREATMENT 222, 222 (2013). 
360. See WHO Model List of Essential Medicines, supra note 40. 
361. See The Facts about Buprenorphine for Treatment of Opioid Addiction, 
supra note 78, at 3. 
362. See Z. Schuman-Olivier et al., Self-Treatment: Illicit Buprenorphine Use 
by Opioid-Dependent Treatment Seekers, 39 J. SUBSTANCE ABUSE 41, 46 
(2010). 
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Buprenorphine was approved by the FDA in 2002.363  Shortly 
before its approval, the DEA rescheduled it from Schedule V to 
Schedule III.  In 2000, Congress passed the Drug Addiction and 
Treatment (DATA).364  DATA permitted physicians to prescribe 
buprenorphine for opioid dependence treatment, but it also placed 
strict limits on buprenorphine treatment.365  After two amendments, 
DATA currently allows physicians with a DATA waiver to treat up 
to 30 patients during their first waiver year, and up to 100 patients 
thereafter.366  Unfortunately, very few physicians actually have a 
DATA waiver, and the waiting lines for these physicians can be very 
long.367  Even though any licensed physician who obtains a DATA 
waiver can prescribe buprenorphine, most physicians with DATA 
waivers are specialists, not primary care doctors.368  This is 
unfortunate, as patients tend to have better access to primary care 
doctors than to specialists, due to financial and geographic barriers.369   
Buprenorphine is underutilized in the U.S. Reasons include the 
following: cultural stigma against MAT; bias from Narcotics 
Anonymous (NA) and many mental health counselors against MAT; 
the dominant cultural paradigm of “abstinence-only” treatment; cost; 
Medicaid limits; patient limits and other restrictions in DATA; and 
concerns about diversion.370 
The TREAT Act was first introduced in the Senate in 2013 by 
Senator Markey (D).371  It was reintroduced in both the Senate and 
the House of Representatives in 2015.  The TREAT Act would amend 
current law in two fundamental ways.  First, it would allow nurse 
practitioners and physician assistants who meet statutory 
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requirements to prescribe buprenorphine.372  Second, it would allow 
qualified practitioners to treat up to 100 patients at any time during 
the first waiver year and to treat an unlimited number of patients 
thereafter.373  By allowing more health practitioners to prescribe 
buprenorphine and by loosening patient limits, the TREAT Act has 
the potential to increase public access to buprenorphine.  For these 
reasons, the TREAT Act has had strong support from physician 
associations.374   
Even with its many benefits, the TREAT Act is still only a step 
in the right direction. As this article suggests, the Act would benefit 
from the several key additions. First, there must be increased federal 
funding for educational grants. Second, there must be federal financial 
incentives for states to remove Medicaid lifetime-limits on 
buprenorphine treatment Next, the Act should provide for federal 
block grants to partially cover the costs of the certification course 
required for some health practitioners Finally, the TREAT Act should 
increase federal funding for grants to study underuse of MAT and 
methods to expand its use. With these modifications, the TREAT Act 
would be a stronger response to the opioid crisis facing America.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
372. See id. 
373. See id. 
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